AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

 

 Permissions and Reprints

Abstract

Therapeutic drug monitoring (TDM), i. e., the quantification of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefit from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefits of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced significantly, and new psychopharmacologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defined ranging from “strongly recommended” to “potentially useful”. Evidence-based “therapeutic reference ranges” and “dose related reference ranges” were elaborated after an extensive literature search and a structured internal review process. A “laboratory alert level” was introduced, i. e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrate- and inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profit from such a joint effort.

• References

• 1 Abbott NJ, Patabendige AA, Dolman DE et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25
  CrossrefPubMedGoogle Scholar
• 2 Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985; 232: 183-188
  PubMedGoogle Scholar
• 3 Adam K, Oswald I. Effects of lormetazepam and of flurazepam on sleep. Br J Clin Pharmacol 1984; 17: 531-538
  CrossrefPubMedGoogle Scholar
• 4 Adamiak U, Kaldonska M, Klodowska-Duda G et al. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol 2010; 33: 135-141
  CrossrefPubMedGoogle Scholar
• 5 Addington D. Best practices: improving quality of care for patients with first-episode psychosis. Psychiatr Serv 2009; 60: 1164-1166
  CrossrefPubMedGoogle Scholar
• 6 Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed?. Eur Arch Psychiatry Clin Neurosci 2005; 55: 387-400
  PubMedGoogle Scholar
• 7 Aichhorn W, Marksteiner J, Walch T et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21: 81-85
  CrossrefPubMedGoogle Scholar
• 8 Aichhorn W, Weiss U, Marksteiner J et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005; 19: 395-401
  CrossrefPubMedGoogle Scholar
• 9 Aichhorn W, Whitworth AB, Weiss ME et al. Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Saf 2006; 29: 587-598
  CrossrefPubMedGoogle Scholar
• 10 Åkerblad AC, Bengtsson F, Ekselius L et al. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. Int Clin Psychopharmacol 2003; 18: 347-354
  CrossrefPubMedGoogle Scholar
• 11 Åkerblad AC, Bengtsson F, Holgersson M et al. Identification of primary care patients at risk of nonadherence to antidepressant treatment. Patient Prefer Adherence 2008; 2: 379-386
  PubMedGoogle Scholar
• 12 Aklillu E, Kalow W, Endrenyi L et al. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007; 17: 989-993
  CrossrefPubMedGoogle Scholar
• 13 Akutsu T, Kobayashi K, Sakurada K et al. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007; 35: 72-78
  PubMedGoogle Scholar
• 14 Albers LJ, Ozdemir V, Marder SR et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol 2005; 25: 170-174
  CrossrefPubMedGoogle Scholar
• 15 Alderman J, Wolkow R, Fogel IM. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol 2006; 16: 117-129
  CrossrefPubMedGoogle Scholar
• 16 Allen MH, Hirschfeld RM, Wozniak PJ et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272-275
  CrossrefPubMedGoogle Scholar
• 17 Allqvist A, Miura J, Bertilsson L et al. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol 2007; 63: 173-179
  CrossrefPubMedGoogle Scholar
• 18 Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214
  CrossrefPubMedGoogle Scholar
• 19 Althaus M, Retzow A, Castell JV et al. In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica 2000; 30: 1033-1045
  CrossrefPubMedGoogle Scholar
• 20 Aman MG, Vinks AA, Remmerie B et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopment disorders. Clin Therap 2007; 29: 1476-1486
  CrossrefPubMedGoogle Scholar
• 21 Anderson D, Reed S, Lintemoot J et al. A first look at duloxetine (Cymbalta^®) in a post-mortem laboratory. J Analyt Toxicology 2006; 30: 576-579
  PubMedGoogle Scholar
• 22 Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008
  CrossrefPubMedGoogle Scholar
• 23 Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22: 343-396
  CrossrefPubMedGoogle Scholar
• 24 Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35-51
  CrossrefPubMedGoogle Scholar
• 25 Aps JK, Martens LC. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005; 150: 119-131
  CrossrefPubMedGoogle Scholar
• 26 Arakawa R, Ito H, Takano A et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008; 197: 229-235
  CrossrefPubMedGoogle Scholar
• 27 Aravagiri M, Marder SR, Yuwiler A et al. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 1995; 13: 235-247
  CrossrefPubMedGoogle Scholar
• 28 Aravagiri M, Teper Y, Marder SR. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 1999; 20: 369-377
  CrossrefPubMedGoogle Scholar
• 29 Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998; 139: 356-363
  CrossrefPubMedGoogle Scholar
• 30 Åsberg M, Cronholm B, Sjöqvist F et al. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 1970; 5726: 18-21
  PubMedGoogle Scholar
• 31 Åsberg M, Crönholm B, Sjöqvist F et al. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971; 3: 331-334
  CrossrefPubMedGoogle Scholar
• 32 Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M et al. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 2008; 30: 108-112
  CrossrefPubMedGoogle Scholar
• 33 Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008; 30: 462-466
  PubMedGoogle Scholar
• 34 Bachus R, Bickel U, Thomsen T et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661-668
  CrossrefPubMedGoogle Scholar
• 35 Backman JT, Olkkola KT, Ojala M et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253-257
  CrossrefPubMedGoogle Scholar
• 36 Bagli M, Höflich G, Rao ML et al. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Int J Clin Pharmacol Ther 1995; 33: 646-652
  PubMedGoogle Scholar
• 37 Baker GB, Urichuk LJ, McKenna KF et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999; 19: 411-426
  CrossrefPubMedGoogle Scholar
• 38 Bakken GV, Rudberg I, Christensen H et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 2009; 37: 254-258
  CrossrefPubMedGoogle Scholar
• 39 Balant LP, Balant-Gorgia AE, Eisele R et al. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. Pharmacopsychiatry 1989; 22: 250-254
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Balant-Gorgia AE, Eisele R, Aeschlimann JM et al. Plasma flupentixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit 1985; 7: 411-414
  CrossrefPubMedGoogle Scholar
• 41 Barbhaiya RH, Shukla UA, Pfeffer M et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46: 41-47
  PubMedGoogle Scholar
• 42 Bareggi SR, Bianchi L, Cavallaro R et al. Citalopram concentrations and response in obsessive-compulsive disorder – Preliminary results. CNS Drugs 2004; 18: 329-335
  CrossrefPubMedGoogle Scholar
• 43 Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008; 40: 553-624
  CrossrefPubMedGoogle Scholar
• 44 Baruzzi A, Bordo B, Bossi L et al. Plasma levels of di-no-propylacetate and clonazepam in epileptic patients. Int J Clin Pharmacol Biopharm 1977; 15: 403-408
  PubMedGoogle Scholar
• 45 Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med 2003; 348: 2526-2534
  Google Scholar
• 46 Bauer M, Whybrow PC, Angst J et al. World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43
  CrossrefPubMedGoogle Scholar
• 47 Bauer S, David Rudd G, Mylius V et al. Lacosamide intoxication in attempted suicide. Epilepsy Behav 2010; 17: 549-551
  CrossrefPubMedGoogle Scholar
• 48 Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-469
  CrossrefPubMedGoogle Scholar
• 49 Baumann P, Barbe R, Vabre-Bogdalova A et al. Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. J Clin Psychopharmacol 2006; 26: 679-681
  CrossrefPubMedGoogle Scholar
• 50 Baumann P, Hiemke C, Ulrich S et al. Le dosage plasmatique des médicaments psychotropes à des fins thérapeutiques: recommandations du groupe d’experts AGNP-TDM. Rev Med Suisse 2006; 2: 1413-1418
  PubMedGoogle Scholar
• 51 Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
  Article in Thieme ConnectPubMedGoogle Scholar
• 52 Baumann P, Ulrich S, Eckermann G et al. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 2005; 7: 231-247
  PubMedGoogle Scholar
• 53 Baumann P, Zullino DF, Eap CB. Enantiomers’ potential in psychopharmacology – a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433-444
  PubMedGoogle Scholar
• 54 Bazire S. Psychotropic Drug Directory 2010. Aberdeen: Healthcomm UK Ltd; 2011
  Google Scholar
• 55 Beasley Jr CM, Stauffer VL, Liu-Seifert H et al. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 2007; 27: 252-258
  CrossrefPubMedGoogle Scholar
• 56 Bech P, Gex-Fabry M, Aubry JM et al. Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states. Nord J Psychiatry 2006; 60: 181-182
  CrossrefPubMedGoogle Scholar
• 57 Becquemont L, Mouajjah S, Escaffre O et al. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27: 1068-1073
  PubMedGoogle Scholar
• 58 Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23: 229-232
  CrossrefPubMedGoogle Scholar
• 59 Benedetti MS, Whomsley R, Poggesi I et al. Drug metabolism and pharmacokinetics. Drug Metab Rev 2009; 41: 344-390
  CrossrefPubMedGoogle Scholar
• 60 Benetton SA, Fang C, Yang YO et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 2007; 22: 78-87
  CrossrefPubMedGoogle Scholar
• 61 Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM “nouveau”. Ther Drug Monit 2004; 26: 145-151
  CrossrefPubMedGoogle Scholar
• 62 Bennett Jr JP, Piercey MF. Pramipexole: a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci 1999; 163: 25-31
  CrossrefPubMedGoogle Scholar
• 63 Bergemann N, Frick A, Parzer P et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004; 37: 63-68
  Article in Thieme ConnectPubMedGoogle Scholar
• 64 Bergemann N, Kopitz J, Kress KR et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacology 2004; 14: 245-250
  CrossrefPubMedGoogle Scholar
• 65 Bergemann N, Rommel F, Conca A. Therapeutisches Drug-Monitoring von Psychopharmaka in der Schwangerschaft. J Neurol Neurochir Psychiatr 2009; 10: 38-40
  PubMedGoogle Scholar
• 66 Bergmann TK, Bathum L, Brøsen K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur J Clin Pharmacol 2001; 57: 123-127
  CrossrefPubMedGoogle Scholar
• 67 Bergstrom RF, Cerimele BJ. Olanzapine in subjects with and without renal failure (data on file). Lilly Laboratory for Clinical Research. Eli Lilly and Co. 1996
  PubMedGoogle Scholar
• 68 Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit 2005; 27: 451-456
  CrossrefPubMedGoogle Scholar
• 69 Bertelsen KM, Venkatakrishnan K, von Moltke LL et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 289-293
  CrossrefPubMedGoogle Scholar
• 70 Berwaerts J, Cleton A, Rossenu S et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010; 24: 1011-1018
  CrossrefPubMedGoogle Scholar
• 71 Bigliani V, Mulligan RS, Acton PD et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000; 150: 132-140
  CrossrefPubMedGoogle Scholar
• 72 Birkenhäger TK, van den Broek WW, Moleman P et al. Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?. Psychopharmacology (Berl) 2005; 181: 595-599
  CrossrefPubMedGoogle Scholar
• 73 Bjerkenstedt L, Flyckt L, Overø KF et al. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985; 28: 553-557
  CrossrefPubMedGoogle Scholar
• 74 Bjørndal N, Bjerre M, Gerlach J et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology (Berl) 1980; 67: 17-23
  CrossrefPubMedGoogle Scholar
• 75 Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs Today 1995; 31: 613-619
  PubMedGoogle Scholar
• 76 Bockbrader HN, Burger P, Knapp L et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia 2011; 52: 248-257
  PubMedGoogle Scholar
• 77 Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49: 661-669
  CrossrefPubMedGoogle Scholar
• 78 Bogaards JJ, Hissink EM, Briggs M et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci 2000; 12: 117-124
  CrossrefPubMedGoogle Scholar
• 79 Bomsien S, Aderjan R, Mattern R et al. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur J Clin Pharmacol 2006; 62: 639-643
  CrossrefPubMedGoogle Scholar
• 80 Bond A, Seijas D, Dawling S et al. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994; 89: 821-830
  CrossrefPubMedGoogle Scholar
• 81 Bondolfi G, Morel F. Crettol et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27: 539-543
  CrossrefPubMedGoogle Scholar
• 82 Bont L, Bosker HA, Brus F et al. Torsade de pointes after pipamperone intoxication. Pharm World Sci 1998; 20: 137
  CrossrefPubMedGoogle Scholar
• 83 Borgstrom L, Larsson H, Molander L. Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol 1982; 23: 173-176
  CrossrefPubMedGoogle Scholar
• 84 Borys DJ, Setzer SC, Ling LJ et al. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992; 10: 115-120
  PubMedGoogle Scholar
• 85 Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol 2008; 4: 18-20
  CrossrefPubMedGoogle Scholar
• 86 Brachtendorf L, Jetter A, Beckurts KT et al. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002; 90: 144-149
  CrossrefPubMedGoogle Scholar
• 87 Brahmi N, Kouraichi N, Abderrazek H et al. Clinical experience with carbamazepine overdose: relationship between serum concentration and neurological severity. J Clin Psychopharmacol 2008; 28: 241-243
  CrossrefPubMedGoogle Scholar
• 88 Brandt C, Baumann P, Eckermann G et al. Therapeutic drug monitoring in Epileptologie und Psychiatrie (Therapeutic drug monitoring in epileptology and psychiatry). Nervenarzt 2008; 79: 167-174
  CrossrefPubMedGoogle Scholar
• 89 Bressan RA, Erlandsson K, Jones HM et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413-1420
  CrossrefPubMedGoogle Scholar
• 90 Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptyline oxide in man. Drug Metab Rev 2004; 36: 723-746
  CrossrefPubMedGoogle Scholar
• 91 Breyer-Pfaff U, Brinkschulte M, Rein W et al. Prediction and evaluation criteria in perazine therapy of acute schizophrenics pharmacokinetic data. Pharmacopsychiatry 1983; 16: 160-165
  Article in Thieme ConnectPubMedGoogle Scholar
• 92 Breyer-Pfaff U, Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol 2004; 56: 1601-1606
  CrossrefPubMedGoogle Scholar
• 93 Brockmöller J, Kirchheiner J, Schmider J et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452
  CrossrefPubMedGoogle Scholar
• 94 Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393-396
  CrossrefPubMedGoogle Scholar
• 95 Brøsen K, Gram LF, Klysner R et al. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986; 30: 43-49
  CrossrefPubMedGoogle Scholar
• 96 Brøsen K, Klysner R, Gram LF et al. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30: 679-684
  CrossrefPubMedGoogle Scholar
• 97 Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11: 275-283
  CrossrefPubMedGoogle Scholar
• 98 Bruijn JA, Moleman P, Mulder PG et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl) 1996; 127: 231-237
  CrossrefPubMedGoogle Scholar
• 99 Brünen S, Vincent DP, Baumann P et al. Therapeutic Drug Monitoring (TDM) for drugs used in the treatment of substance related disorders. Literature review using a TDM appropriateness rating scale. Ther Drug Monit 2011; in press
  PubMedGoogle Scholar
• 100 Brunton LL, Lazo JS, Parker KL. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11^th edn. McGraw-Hill; New York: 2006
  Google Scholar
• 101 Buchanan RW, Kreyenbuhl J, Kelly DL et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93
  Google Scholar
• 102 Buckley NA, Dawson AH, Whyte IM et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994; 343: 159-162
  CrossrefPubMedGoogle Scholar
• 103 Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants – cost implications and relevance to clinical practice. Clin Pharmacokinet 1999; 37: 147-165
  CrossrefPubMedGoogle Scholar
• 104 Byerly MJ, Thompson A, Carmody T et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007; 58: 844-847
  CrossrefPubMedGoogle Scholar
• 105 Caccia S, Garattini S. Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol Res 1992; 26: 317-329
  PubMedGoogle Scholar
• 106 Caccia S, Pasia L, Nobili L. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010; 4: 33-48
  PubMedGoogle Scholar
• 107 Callaghan JT, Bergstrom RF, Ptak LR et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-193
  CrossrefPubMedGoogle Scholar
• 108 Canal M, Desanti CR, Santoni JP. A new oral formulation of tiapride (drops): pharmacokinetic profile and therapeutic applications. Clin Drug Investig 1998; 15: 455-460
  CrossrefPubMedGoogle Scholar
• 109 Canal-Raffin M, Déridet E, Titier K et al. Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindone and norsertindole, in human plasma. J Chromatography B 2005; 814: 61-67
  CrossrefPubMedGoogle Scholar
• 110 Canal-Raffin M, Titier K, Déridet E et al. Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs. Biopharm Drug Dispos 2006; 27: 171-179
  CrossrefPubMedGoogle Scholar
• 111 Carlsson B, Olsson G, Reis M et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit 2001; 23: 658-664
  CrossrefPubMedGoogle Scholar
• 112 Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007; 68: 1540-1545
  CrossrefPubMedGoogle Scholar
• 113 Castberg I, Spigset O. Prescribing pattern and use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Ther Drug Monit 2008; 30: 597-603
  CrossrefPubMedGoogle Scholar
• 114 Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B Biomed Sci Appl 1997; 689: 175-180
  CrossrefPubMedGoogle Scholar
• 115 Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009; 37: 2055-2060
  CrossrefPubMedGoogle Scholar
• 116 Centerholt C, Ekblom M, Odergren T et al. Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. Eur J Clin Pharmacol 2003; 59: 117-122
  PubMedGoogle Scholar
• 117 Chakraborty BS, Midha KK, McKay G et al. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. J Pharm Sci 1989; 78: 796-801
  CrossrefPubMedGoogle Scholar
• 118 Chan V, Morris RG, Ilett KF et al. Population pharmacokinetics of lamotrigine. Ther Drug Monit 2001; 23: 630-635
  CrossrefPubMedGoogle Scholar
• 119 Chang YC, Lane HY, Yang KH et al. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006; 26: 554-559
  CrossrefPubMedGoogle Scholar
• 120 Chawarski MC, Schottenfeld RS, O’Connor PG et al. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend 1999; 55: 157-163
  CrossrefPubMedGoogle Scholar
• 121 Chen H, Grover S, Yu L et al. Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. Chem Res Toxicol 2010; 23: 159-170
  CrossrefPubMedGoogle Scholar
• 122 Chen P, Tanasijevic MJ, Schoenenberger RA et al. A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring. Am J Clin Pathol 2003; 119: 432-438
  CrossrefPubMedGoogle Scholar
• 123 Cheng YF, Paalzow LK, Bondesson U et al. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology (Berl) 1987; 91: 410-414
  CrossrefPubMedGoogle Scholar
• 124 Chenu F, Batten LA, Zernig G et al. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry 2009; 70: 958-966
  CrossrefPubMedGoogle Scholar
• 125 Chermá MD, Löfgren UB, Almkvist G et al. Assessment of the prescription of antidepressant drugs in elderly nursing home patients. J Clin Psychopharmacol 2008; 28: 424-431
  CrossrefPubMedGoogle Scholar
• 126 Chermá MD, Reis M, Hägg S et al. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. Ther Drug Monit 2008; 30: 682-688
  CrossrefPubMedGoogle Scholar
• 127 Chetty M, Gouws E, Miller R et al. The use of a side effect as a qualitative indicator of plasma chlorpromazine levels. Eur Neuropsychopharmacol 1999; 9: 77-82
  CrossrefPubMedGoogle Scholar
• 128 Choc MG, Hsuan F, Honigfeld G et al. Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7: 347-351
  CrossrefPubMedGoogle Scholar
• 129 Choong E, Dobrinas M, Carrupt PA et al. The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. Expert Opin Drug Metab Toxicol 2010; 6: 953-965
  CrossrefPubMedGoogle Scholar
• 130 Ciraulo DA, Hitzemann RJ, Somoza E et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 2006; 46: 179-192
  PubMedGoogle Scholar
• 131 Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010; 64: 216-239
  PubMedGoogle Scholar
• 132 Citrome L, Stauffer VL, Chen L et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia. J Clin Psychopharmacol 2009; 29: 278-283
  CrossrefPubMedGoogle Scholar
• 133 Collins N, Barnes TR, Shingleton-Smith A et al. Standards of lithium monitoring in mental health trusts in the UK. BMC Psychiatry 2010; 10: 80
  CrossrefPubMedGoogle Scholar
• 134 Conca A, Schmidt E, Pastore M et al. Therapeutic drug monitoring in Italian psychiatry. Pharmacopsychiatry 2011; 44: 259-262
  Article in Thieme ConnectPubMedGoogle Scholar
• 135 Contin M, Riva R, Martinelli P et al. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled is release in parkinsonian patients. Eur J Clin Pharmacol 1998; 54: 303-308
  CrossrefPubMedGoogle Scholar
• 136 Cooper TB. Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 1978; 3: 14-38
  CrossrefPubMedGoogle Scholar
• 137 Coppen A, Kopera H. Workshop on the clinical pharmacology and efficacy of mianserin. Br J Clin Pharmacol 1978; 5: 91S-99S
  PubMedGoogle Scholar
• 138 Correll CU, Malhotra AK, Kaushik S et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063-2065
  CrossrefPubMedGoogle Scholar
• 139 Couchman L, Morgan PE, Spencer EP et al. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Ther Drug Monit 2010; 32: 624-627
  CrossrefPubMedGoogle Scholar
• 140 Couchman L, Morgan PE, Spencer EP et al. Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010; 32: 438-447
  CrossrefPubMedGoogle Scholar
• 141 Coulomb F, Ducret F, Laneury JP et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000; 40: 482-487
  PubMedGoogle Scholar
• 142 Cournoyer G, De Montigny C, Ouellette J et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 1987; 7: 385-393
  PubMedGoogle Scholar
• 143 Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010; 42: 202-217
  PubMedGoogle Scholar
• 144 Crettol S, Besson J, Croquette-Krokar M et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1722-1727
  CrossrefPubMedGoogle Scholar
• 145 Crettol S, Déglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668-681
  CrossrefPubMedGoogle Scholar
• 146 Crettol S, Déglon JJ, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78: 593-604
  CrossrefPubMedGoogle Scholar
• 147 Cummings J, Lefèvre G, Small G et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69 (Suppl. 01) S10-S13
  PubMedGoogle Scholar
• 148 Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982; 4: 33-40
  CrossrefPubMedGoogle Scholar
• 149 Dahl SG, Strandjord RE, Sigfusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 1977; 11: 305-310
  CrossrefPubMedGoogle Scholar
• 150 Darby JK, Pasta DJ, Wilson MG et al. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig 2008; 28: 553-564
  PubMedGoogle Scholar
• 151 Daviss WB, Perel JM, Birmaher B et al. Steady-state clinical pharmacokinetics of bupropion extended-release in youths. J Am Acad Child Adolesc Psychiatry 2006; 45: 1503-1509
  CrossrefPubMedGoogle Scholar
• 152 Daviss WB, Perel JM, Brent DA et al. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study. Ther Drug Monit 2006; 28: 190-198
  CrossrefPubMedGoogle Scholar
• 153 Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982; 15: 56-61
  CrossrefPubMedGoogle Scholar
• 154 de Lange EC. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004; 56: 1793-1809
  CrossrefPubMedGoogle Scholar
• 155 de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003; 6: 57-72
  CrossrefPubMedGoogle Scholar
• 156 de Leon J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectr 2006; 11 (Suppl. 03) 8-12
  PubMedGoogle Scholar
• 157 de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects talking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 2007; 27: 241-245
  CrossrefPubMedGoogle Scholar
• 158 de Leon J, Greenlee B, Barber J et al. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil 2009; 30: 613-669
  CrossrefPubMedGoogle Scholar
• 159 de Leon J, Susce MT, Pan RM et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93-102
  Article in Thieme ConnectPubMedGoogle Scholar
• 160 de Leon J, Susce MT, Pan RM et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27
  CrossrefPubMedGoogle Scholar
• 161 de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51: 80-88
  CrossrefPubMedGoogle Scholar
• 162 de Mey C, Althaus M, Ezan E et al. Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. Clin Pharmacol Ther 2001; 70: 142-148
  CrossrefPubMedGoogle Scholar
• 163 de Vries MH, Raghoebar M, Mathlener IS et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14: 493-498
  CrossrefPubMedGoogle Scholar
• 164 de Wit M, Best AM, Epstein SK et al. Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. Int J Clin Pharmacol Ther 2006; 44: 466-473
  PubMedGoogle Scholar
• 165 Degen J, Wölke E, Seiberling M et al. Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure. Med Klin (Munich) 1993; 88: 129-133
  PubMedGoogle Scholar
• 166 Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 (Suppl. 01) S39-S45
  Article in Thieme ConnectPubMedGoogle Scholar
• 167 Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003; 42: 633-645
  CrossrefPubMedGoogle Scholar
• 168 Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261-309
  CrossrefPubMedGoogle Scholar
• 169 Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010; 71: 649-650
  CrossrefPubMedGoogle Scholar
• 170 Delva NJ, Hawken ER. Preventing lithium intoxication. Guide for physicians. Can Fam Physician 2001; 47: 1595-1600
  PubMedGoogle Scholar
• 171 Desta Z, Kerbusch T, Soukhova N et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428-437
  PubMedGoogle Scholar
• 172 Deuschle M, Härtter S, Hiemke C et al. Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology (Berl) 1997; 131: 19-22
  CrossrefPubMedGoogle Scholar
• 173 DeVane CL, Boulton DW, Miller LF et al. Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmacol 1999; 2: 17-23
  CrossrefPubMedGoogle Scholar
• 174 DeVane CL, Stowe ZN, Donovan JL et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006; 20 (Suppl) 54-59
  CrossrefPubMedGoogle Scholar
• 175 Diaz FJ, de Leon J, Josiassen RC et al. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005; 72: 131-135
  CrossrefPubMedGoogle Scholar
• 176 Diaz FJ, Santoro V, Spina E et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91
  Article in Thieme ConnectPubMedGoogle Scholar
• 177 Dingemanse J, Jorga K, Zürcher G et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50: 47-55
  CrossrefPubMedGoogle Scholar
• 178 Dockens RC, Salazar DE, Fulmor IE et al. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J Clin Pharmacol 2006; 46: 1308-1312
  PubMedGoogle Scholar
• 179 Doose DR, Walker SA, Gisclon LG et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36: 884-891
  PubMedGoogle Scholar
• 180 Doran A, Obach RS, Smith BJ et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33: 165-174
  PubMedGoogle Scholar
• 181 dos Santos FM, Gonçalves JC, Caminha R et al. Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers. Ther Drug Monit 2009; 31: 566-574
  CrossrefPubMedGoogle Scholar
• 182 Dunbar JL, Turncliff RZ, Hayes SC et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 2007; 68: 862-870
  PubMedGoogle Scholar
• 183 Dutheil F, Jacob A, Dauchy S et al. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin Drug Metab Toxicol 2010; 6: 1161-1174
  CrossrefPubMedGoogle Scholar
• 184 Dvorchik BH, Vesell ES. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem 1976; 22: 868-878
  PubMedGoogle Scholar
• 185 Eagles JM, McCann I, MacLeod TN et al. Lithium monitoring before and after the distribution of clinical practice guidelines. Acta Psychiatr Scand 2000; 101: 349-353
  CrossrefPubMedGoogle Scholar
• 186 Eap CB, Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. J Chromatogr B Biomed Appl 1996; 686: 51-63
  CrossrefPubMedGoogle Scholar
• 187 Eap CB, Bender S, Gastpar M et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209-214
  CrossrefPubMedGoogle Scholar
• 188 Eap CB, Bertschy G, Baumann P et al. High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry 1998; 55: 89-90
  CrossrefPubMedGoogle Scholar
• 189 Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41: 1153-1193
  Google Scholar
• 190 Eap CB, Finkbeiner T, Gastpar M et al. Replacement of R-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the R/S ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996; 50: 385-389
  CrossrefPubMedGoogle Scholar
• 191 Eap CB, Koeb L, Baumann P. Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. J Chromatogr 1994; 652: 97-103
  CrossrefPubMedGoogle Scholar
• 192 Eap CB, Lima CA, Macciardi F et al. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit 1998; 20: 7-13
  CrossrefPubMedGoogle Scholar
• 193 Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137
  CrossrefPubMedGoogle Scholar
• 194 Egberts K, Mehler-Wex C, Gerlach M 2011 Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 2011; 44: 249-253
  Article in Thieme ConnectPubMedGoogle Scholar
• 195 Eggert Hansen C, Rosted Christensen T, Elley J et al. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 1976; 3: 915-923
  CrossrefPubMedGoogle Scholar
• 196 Ellinwood EHJR, Heatherly DG, Nikaido AM et al. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 1985; 86: 392-399
  CrossrefPubMedGoogle Scholar
• 197 Ereshefsky L, Jann MW, Saklad SR et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20: 329-332
  CrossrefPubMedGoogle Scholar
• 198 Evans LE, Bett JH, Cox JR et al. The bioavailability of oral and parenteral chlorimipramine (Anafranil). Prog Neuropsychopharmacol 1980; 4: 293-302
  CrossrefPubMedGoogle Scholar
• 199 Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491
  CrossrefPubMedGoogle Scholar
• 200 Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76: 178-184
  CrossrefPubMedGoogle Scholar
• 201 Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when?. Basic Clin Pharmacol Toxicol 2005; 97: 125-134
  CrossrefPubMedGoogle Scholar
• 202 Faessel HM, Gibbs MA, Clarc DJ et al. Multiple-does pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 2006; 46: 1439-1448
  PubMedGoogle Scholar
• 203 Faiman MD, Jensen JC, Lacoursiere RB. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 1984; 36: 520-526
  CrossrefPubMedGoogle Scholar
• 204 Falkai P, Wobrock T, Lieberman J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132-191
  Google Scholar
• 205 Falkai P, Wobrock T, Lieberman J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006; 7: 5-40
  Google Scholar
• 206 Fanton L, Bévalot F, Grait H et al. Fatal intoxication with milnacipran. J Forensic Leg Med 2008; 15: 388-390
  CrossrefPubMedGoogle Scholar
• 207 Farde L, Nordström AL, Wiesel FA et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-544
  Google Scholar
• 208 Feng Y, Pollock BG, Coley K et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. J Clin Pharmacol 2008; 66: 629-639
  PubMedGoogle Scholar
• 209 Feng Y, Pollock BG, Ferrell RE et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006; 61: 558-569
  CrossrefPubMedGoogle Scholar
• 210 Fenner KS, Troutman MD, Kempshall S et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173-181
  CrossrefPubMedGoogle Scholar
• 211 Ferrari A, Bertolotti M, Dell Utri A et al. Serum time course of naltrexone and 6ß-naltrexol levels during long term treatment in drug addicts. Drug Alcohol Depend 1998; 52: 211-220
  CrossrefPubMedGoogle Scholar
• 212 Figueroa C, Brecher M, Hamer-Maansson JE et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 199-204
  CrossrefPubMedGoogle Scholar
• 213 Findling RL, Reed MD, Myers C et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 952-959
  CrossrefPubMedGoogle Scholar
• 214 Fitzgerald PB, Kapur S, Remington G et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl) 2000; 149: 1-5
  CrossrefPubMedGoogle Scholar
• 215 Flanagan RJ. Developing an analytical toxicology service: principles and guidance. Toxicol Rev 2004; 23: 251-263
  CrossrefPubMedGoogle Scholar
• 216 Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed?. Clin Neuropharmacol 2006; 29: 350-360
  CrossrefPubMedGoogle Scholar
• 217 Fogelman SM, Schmider J, Venkatakrishnan K et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20: 480-490
  CrossrefPubMedGoogle Scholar
• 218 Fontaine R, Mercier P, Beaudry P et al. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 1986; 74: 451-458
  CrossrefPubMedGoogle Scholar
• 219 Food and Drug Administration . Guidance for industry: bioanalytical method validation. 2001 http://www.fda.gov/cvm
  PubMedGoogle Scholar
• 220 Foti RS, Rock DA, Wienkers LC et al. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 2010; 38: 981-987
  CrossrefPubMedGoogle Scholar
• 221 Fountoulakis KN. An update of evidence-based treatment of bipolar depression: where do we stand?. Curr Opin Psychiatry 2010; 23: 19-24
  CrossrefPubMedGoogle Scholar
• 222 Fric M, Pfuhlmann B, Laux G et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 2008; 41: 151-155
  Article in Thieme ConnectPubMedGoogle Scholar
• 223 Frieboes RM, Sonntag A, Yassouridis A et al. Clinical outcome after trimipramine in patients with delusional depression – a pilot study. Pharmacopsychiatry 2003; 36: 12-17
  Article in Thieme ConnectPubMedGoogle Scholar
• 224 Friedman H, Greenblatt DJ, Peters GR et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992; 52: 139-150
  CrossrefPubMedGoogle Scholar
• 225 Fritze J, Laux G, Sofic E et al. Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines. Psychopharmacology (Berl) 1989; 99: 252-256
  CrossrefPubMedGoogle Scholar
• 226 Fröscher W, Schier KR, Hoffmann M et al. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 2005; 7: 237-248
  PubMedGoogle Scholar
• 227 Fudio S, Borobia AM, Piñana E et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 2010; 626: 200-204
  CrossrefPubMedGoogle Scholar
• 228 Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32: 333-341
  CrossrefPubMedGoogle Scholar
• 229 Furlanut M, Montanari G, Benetello P et al. Steady-state serum concentrations of imipramine, its main metabolites and clinical response in primary enuresis. Pharmacol Res 1989; 21: 561-566
  CrossrefPubMedGoogle Scholar
• 230 Furukori H, Kondo T, Yasui N et al. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology (Berl) 1999; 145: 189-192
  CrossrefPubMedGoogle Scholar
• 231 Gaertner HJ, Golfinopoulos G, Breyer-Pfaff U. Response to Maprotiline treatment in depressive patients, relationship to urinary MHPG excretion, and plasma drug level. Pharmacopsychiatria 1982; 15: 170-174
  Article in Thieme ConnectPubMedGoogle Scholar
• 232 Gaertner I, Gaertner HJ, Vonthein R et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 2001; 21: 305-310
  CrossrefPubMedGoogle Scholar
• 233 Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11: 203-226
  CrossrefPubMedGoogle Scholar
• 234 Gelenberg AJ. A review of the current guidelines for depression treatment. J Clin Psychiatry 2010; 71: e15
  CrossrefPubMedGoogle Scholar
• 235 Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001; 42 (Suppl. 03) 42-45
  PubMedGoogle Scholar
• 236 Gerlach M, Hünnerkopf R, Rothenhöfer S et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 2007; 40: 72-76
  Article in Thieme ConnectPubMedGoogle Scholar
• 237 Gerstenberg G, Aoshima T, Fukasawa T et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003; 167: 443-448
  PubMedGoogle Scholar
• 238 Gervasini G, Carrillo JA, Benitez J. Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin Pharmacokinet 2004; 43: 693-706
  CrossrefPubMedGoogle Scholar
• 239 Gex-Fabry M, Balant-Gorgia AE, Balant LP. Clomipramine concentration as a predictor of delayed response: a naturalistic study. Eur J Clin Pharmacol 1999; 54: 895-902
  CrossrefPubMedGoogle Scholar
• 240 Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53
  CrossrefPubMedGoogle Scholar
• 241 Gex-Fabry M, Balant-Gorgia AE, Balant LP et al. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 2004; 59: 883-891
  CrossrefPubMedGoogle Scholar
• 242 Gex-Fabry M, Gervasoni N, Eap CB et al. Time course of response to paroxetine: influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 892-900
  CrossrefPubMedGoogle Scholar
• 243 Gilles M, Deuschle M, Kellner S et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005; 38: 118-121
  Article in Thieme ConnectPubMedGoogle Scholar
• 244 Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-748
  CrossrefPubMedGoogle Scholar
• 245 Glassman AH, Perel JM, Shostak M et al. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977; 34: 197-204
  CrossrefPubMedGoogle Scholar
• 246 Glassmann AH, Schildkraut JJ, Orsulak PJ et al. Tricyclic antidepressants, blood level measurements and clinical outcome: an APA task force report. Am J Psychiat 1985; 142: 155-162
  PubMedGoogle Scholar
• 247 Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000; 41 (Suppl. 08) S6-S15
  CrossrefPubMedGoogle Scholar
• 248 Gleason MM, Egger HL, Emslie GJ et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46: 1532-1572
  CrossrefPubMedGoogle Scholar
• 249 Glotzbach RK, Preskorn SH. Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology 1982; 78: 25-27
  CrossrefPubMedGoogle Scholar
• 250 Goeringer KE, Raymon L, Christian GD et al. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci 2000; 45: 633-648
  PubMedGoogle Scholar
• 251 Gomolin IH, Smith C, Jeitner TM. Once-daily memantine: pharmacokinetic and clinical considerations. J Am Geriatr Soc 2010; 58: 1812-1813
  CrossrefPubMedGoogle Scholar
• 252 Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192-213
  CrossrefPubMedGoogle Scholar
• 253 Goodnick PJ, Dominguez RA, DeVane CL et al. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol Psychiatry 1998; 44: 629-632
  CrossrefPubMedGoogle Scholar
• 254 Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388
  CrossrefPubMedGoogle Scholar
• 255 Gram LF, Guentert TW, Grange S et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-677
  CrossrefPubMedGoogle Scholar
• 256 Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331-349
  CrossrefPubMedGoogle Scholar
• 257 Grasmäder K, Verwohlt PL, Kühn KU et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry 2005; 38: 113-117
  Article in Thieme ConnectPubMedGoogle Scholar
• 258 Grasmäder K, Verwohlt PL, Rietschel M et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329-336
  PubMedGoogle Scholar
• 259 Greenblatt DJ, Blaskovich PD, Nuwayser ES et al. Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. J Clin Pharmacol 2005; 45: 1288-1293
  PubMedGoogle Scholar
• 260 Greenblatt DJ, Divoll M, Harmatz JS et al. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980; 215: 86-91
  PubMedGoogle Scholar
• 261 Greenblatt DJ, Ehrenberg BL, Gunderman J et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45: 356-365
  CrossrefPubMedGoogle Scholar
• 262 Greenblatt DJ, Friedman H, Burstein ES et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987; 42: 193-200
  CrossrefPubMedGoogle Scholar
• 263 Greenblatt DJ, Gan L, Harmatz JS et al. Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. Br J Clin Pharmacol 2005; 60: 244-248
  CrossrefPubMedGoogle Scholar
• 264 Greenblatt DJ, Harmatz JS, Friedman H et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit 1989; 11: 652-657
  CrossrefPubMedGoogle Scholar
• 265 Greenblatt DJ, Harmatz JS, von Moltke LL et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64: 553-561
  CrossrefPubMedGoogle Scholar
• 266 Greenblatt DJ, Shader RI, Franke K et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68: 57-63
  CrossrefPubMedGoogle Scholar
• 267 Greenblatt DJ, von Moltke LL, Ehrenberg BL et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med 2000; 28: 2750-2757
  CrossrefPubMedGoogle Scholar
• 268 Greenblatt DJ, von Moltke LL, Harmatz JS et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43: 414-422
  PubMedGoogle Scholar
• 269 Greiner C, Hiemke C, Bader W et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 391-394
  CrossrefPubMedGoogle Scholar
• 270 Grimaldi R, Perucca E, Ruberto G et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986; 29: 735-737
  CrossrefPubMedGoogle Scholar
• 271 Grohmann R, Engel RR, Rüther E et al. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004; 37 (Suppl. 01) S4-S11
  Article in Thieme ConnectPubMedGoogle Scholar
• 272 Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications. Occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-977
  CrossrefPubMedGoogle Scholar
• 273 Gründer G, Fellows C, Janouschek H et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 2008; 165: 988-995
  CrossrefPubMedGoogle Scholar
• 274 Gründer G, Hiemke C, Paulzen M et al. Therpaeutic drug concentrations of antidepressants and antipsychotics: Guidance from PET imaging. Pharmacopsychiatry 2011; 44: 236-248
  Article in Thieme ConnectPubMedGoogle Scholar
• 275 Gründer G, Hippius H, Carlsson A. The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009; 8: 197-202
  CrossrefPubMedGoogle Scholar
• 276 Grunze H, Vieta E, Goodwin GM. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10: 85-116
  CrossrefPubMedGoogle Scholar
• 277 Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother 2006; 4: 330-346
  CrossrefPubMedGoogle Scholar
• 278 Guberman A, Couture M, Blaschuk K et al. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci 1990; 17: 311-316
  PubMedGoogle Scholar
• 279 Gunes A, Spina E, Dahl ML et al. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30: 628-633
  CrossrefPubMedGoogle Scholar
• 280 Gupta N. Guidelines for lithium monitoring: are they ideal?. Acta Psychiatr Scand 2001; 104: 76-77
  PubMedGoogle Scholar
• 281 Gupta RN, Dziurdzy SA. Therapeutic monitoring of sertraline. Clin Chem 1994; 40: 498-499
  PubMedGoogle Scholar
• 282 Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol 1999; 48: 71-78
  PubMedGoogle Scholar
• 283 Guy W. editor ECDEU Assessment Manual for Psychopharmacology. Rockville, MD. U.S: Department of Health, Education, and Welfare; 1976
• 284 Haberstroh J, Hampel H, Pantel J. Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice. Neuropsychiatr Dis Treat 2010; 6: 243-253
  PubMedGoogle Scholar
• 285 Haen E, Greiner C, Bader W et al. Wirkstoffkonzentrationsbestimmungen zur Therapieleitung. Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche. Nervenarzt 2008; 79: 558-566
  CrossrefPubMedGoogle Scholar
• 286 Hallett C, Dean BC. Bromazepam: acute benefit-risk assessment in general practice. Curr Med Res Opin 1984; 8: 683-688
  CrossrefPubMedGoogle Scholar
• 287 Hammarberg A, Beck O, Eksborg S et al. Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers. Ther Drug Monit 2010; 32: 489-496
  CrossrefPubMedGoogle Scholar
• 288 Hammarberg A, Jayaram-Lindström N, Berck O et al. The effects of acomprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacol 2009; 205: 53-62
  PubMedGoogle Scholar
• 289 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36
  CrossrefPubMedGoogle Scholar
• 290 Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-283
  CrossrefPubMedGoogle Scholar
• 291 Härtter S, Dingemanse J, Baier D et al. The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 1996; 6: 225-230
  PubMedGoogle Scholar
• 292 Härtter S, Hermes B, Hiemke C. Automated determination of trimipramine and N-desmethyl-trimipramine in human plasma or serum by HPLC with on-line solid phase extraction. J Liq Chromatogr 1995; 18: 3495-3505
  CrossrefPubMedGoogle Scholar
• 293 Härtter S, Hermes B, Szegedi A et al. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther Drug Monit 1994; 16: 400-406
  CrossrefPubMedGoogle Scholar
• 294 Härtter S, Hiemke C. Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr 1992; 578: 273-282
  CrossrefPubMedGoogle Scholar
• 295 Härtter S, Tybring G, Friedberg T et al. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002; 19: 1034-1037
  CrossrefPubMedGoogle Scholar
• 296 Härtter S, Wang X, Weigmann H et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21: 167-174
  CrossrefPubMedGoogle Scholar
• 297 Härtter S, Weigmann H, Hiemke C. Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2000; 740: 135-140
  CrossrefPubMedGoogle Scholar
• 298 Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992; 38: 2082-2086
  PubMedGoogle Scholar
• 299 Hasselstrøm J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004; 26: 486-491
  CrossrefPubMedGoogle Scholar
• 300 Hässler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Dev Disabil Res Rev 2010; 16: 265-272
  CrossrefPubMedGoogle Scholar
• 301 Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?. Ther Drug Monit 2010; 32: 19-29
  CrossrefPubMedGoogle Scholar
• 302 Hazell P, Becker K, Nikkanen EA et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord 2009; 1: 201-210
  CrossrefPubMedGoogle Scholar
• 303 Hegerl U, Bottlender R, Gallinat J et al. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neuroci 1998; 248: 96-103
  PubMedGoogle Scholar
• 304 Heikkinen H, Saraheimo M, Antila S et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique. Eur J Clin Pharmacol 2001; 56: 821-826
  CrossrefPubMedGoogle Scholar
• 305 Heller S, Hiemke C, Stroba G et al. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. Ther Drug Monit 2004; 26: 459-461
  CrossrefPubMedGoogle Scholar
• 306 Hendset M, Hermann M, Lunde H et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63: 1147-1151
  CrossrefPubMedGoogle Scholar
• 307 Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther 1999; 66: 374-379
  CrossrefPubMedGoogle Scholar
• 308 Hermida J, Paz E, Tutor JC. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit 2008; 30: 41-45
  CrossrefPubMedGoogle Scholar
• 309 Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225-238
  CrossrefPubMedGoogle Scholar
• 310 Hiemke C. Clinical utility of drug measurement and pharmacokinetics – therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008; 64: 159-166
  CrossrefPubMedGoogle Scholar
• 311 Hiemke C. Therapeutic drug monitoring in neuropharmacology: does it hold its promises?. Eur Arch Psychiatry Clin Neurosci 2008; 258 (Suppl. 01) 21-27
  CrossrefPubMedGoogle Scholar
• 312 Hiemke C, Baumann P, Laux G et al. Therapeutisches Drug-Monitoring in der Psychiatrie. Konsensus-Leitlinie der AGNP. Psychopharmakotherapie 2005; 12: 166-182
  Google Scholar
• 313 Hiemke C, Dragicevic A, Gründer G et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160
  CrossrefPubMedGoogle Scholar
• 314 Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28
  CrossrefPubMedGoogle Scholar
• 315 Higuchi H, Yoshida K, Takahashi H et al. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol 2003; 18: 255-259
  CrossrefPubMedGoogle Scholar
• 316 Höjer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila) 2008; 46: 336-337
  CrossrefPubMedGoogle Scholar
• 317 Holbrook JM, Parks-Veal P, Mimbs J. Clinical monitoring guidelines for neuroleptic and antidepressant drugs. Central State Hospital, Milledgeville, Georgia. Hosp Pharm 1991; 26: 783-784 787–793
  PubMedGoogle Scholar
• 318 Holzer L, Preuss U, Baumgartner L et al. Quetiapine in adolescents with non-affective psychotic disorders: An open-label trial. Pharmacopsychiatry 2011; 44: 87-95
  Article in Thieme ConnectPubMedGoogle Scholar
• 319 Hooper WD, Dickinson RG, Dunstan PR et al. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. Clin Exp Neurol 1987; 24: 105-112
  PubMedGoogle Scholar
• 320 Horadam VW, Sharp JG, Smilack JD et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981; 94: 454-458
  CrossrefPubMedGoogle Scholar
• 321 Hrdina PD, Lapierre YD. Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients. Ther Drug Monit 1986; 8: 400-406
  CrossrefPubMedGoogle Scholar
• 322 Hsieh YH, Yang YH, Yeh HH et al. Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer’s disease. Electrophoresis 2009; 30: 644-653
  CrossrefPubMedGoogle Scholar
• 323 Hughes J, Gill AM, Mulhearn H et al. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother 1996; 30: 27-30
  PubMedGoogle Scholar
• 324 Hui WK, Mitchell LB, Kavanagh KM et al. Melperone: electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol 1990; 15: 144-149
  CrossrefPubMedGoogle Scholar
• 325 Ilett KF, Blythe TH, Hackett LP et al. Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness. Ther Drug Monit 1993; 15: 351-357
  CrossrefPubMedGoogle Scholar
• 326 Isacsson G, Holmgren P, Druid H et al. The utilization of antidepressants – a key issue in the prevention of suicide: an analysis of 5 281 suicides in Sweden during the period 1992–1994. Acta Psychiatr Scand 1997; 96: 94-100
  CrossrefPubMedGoogle Scholar
• 327 Isbister GK, Hackett LP, Dawson AH et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 2003; 56: 441-450
  CrossrefPubMedGoogle Scholar
• 328 Ishida M, Otani K, Kaneko S et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995; 10: 143-146
  CrossrefPubMedGoogle Scholar
• 329 Iwersen S, Schmoldt A. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. J Anal Toxicol 1996; 20: 301-304
  PubMedGoogle Scholar
• 330 Jaanson P, Marandi T, Kiivet RA et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002; 162: 67-73
  CrossrefPubMedGoogle Scholar
• 331 Janis GC, Markowitz JS. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2007; 81: 346-353
  CrossrefPubMedGoogle Scholar
• 332 Jann MW, Grimsley SR, Gray EC et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24: 161-176
  CrossrefPubMedGoogle Scholar
• 333 Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-739
  CrossrefPubMedGoogle Scholar
• 334 Jaquenoud Sirot E, Knezevic B, Morena GP et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29: 319-326
  CrossrefPubMedGoogle Scholar
• 335 Jaquenoud Sirot E, van der Velden JW, Rentsch K et al. Therapeutic drug monitoring and pharmacogenetic rests as tools in pharmacovigilance. Drug Safety 2006; 29: 735-768
  CrossrefPubMedGoogle Scholar
• 336 Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Therap 2005; 27: 1685-1695
  CrossrefPubMedGoogle Scholar
• 337 Jerling M, Dahl ML, Aberg-Wistedt A et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423-428
  CrossrefPubMedGoogle Scholar
• 338 Ji P, Damle B, Xie J et al. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol 2008; 48: 948-956
  PubMedGoogle Scholar
• 339 Jimmink A, Caminada K, Hunfeld NG et al. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 2008; 30: 365-371
  CrossrefPubMedGoogle Scholar
• 340 Jin Y, Pollock BG, Frank E et al. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. J Clin Pharmacol 2009; 49: 176-184
  PubMedGoogle Scholar
• 341 Jochemsen R, Wesselman JG, Hermans J et al. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol 1983; 16 (Suppl. 02) 285S-290S
  CrossrefPubMedGoogle Scholar
• 342 Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monitor 2003; 25: 347-363
  CrossrefPubMedGoogle Scholar
• 343 Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet 2006; 45: 1061-1075
  CrossrefPubMedGoogle Scholar
• 344 Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26
  PubMedGoogle Scholar
• 345 Johnston JA, Fiedler-Kelly J, Glover ED et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3: 131-140
  PubMedGoogle Scholar
• 346 Jorga KM, Fotteler B, Heizmann P et al. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson’s disease therapy. Eur J Clin Pharmacol 1998; 54: 443-447
  CrossrefPubMedGoogle Scholar
• 347 Jorga KM, Larsen JP, Beiske A et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999; 6: 211-219
  CrossrefPubMedGoogle Scholar
• 348 Jørgensen A. Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol 1980; 18: 355-360
  CrossrefPubMedGoogle Scholar
• 349 Jornil J, Jensen KG, Larsen F et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 2010; 38: 376-385
  CrossrefPubMedGoogle Scholar
• 350 Kandasamy M, Srinivas P, Subramaniam K et al. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes – focus on venlafaxine and O-desmethylvenlafaxine. Eur J Clin Pharmacol 2010; 66: 879-887
  CrossrefPubMedGoogle Scholar
• 351 Kane JM, Leucht S, Carpenter D et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 12 (Suppl) 5-19
  PubMedGoogle Scholar
• 352 Kaplan SA, Jack ML, Weinfeld RE et al. Biopharmaceutical and clinical pharmacokinetic profile of bromazepam. J Pharmacokinet Biopharm 1976; 4: 1-16
  CrossrefPubMedGoogle Scholar
• 353 Kasper S, Dötsch M, Kick H et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13-21
  CrossrefPubMedGoogle Scholar
• 354 Katoh Y, Uchida S, Kawai M et al. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull 2010; 33: 285-288
  CrossrefPubMedGoogle Scholar
• 355 Katon W, Cantrell CR, Sokol MS et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005; 165: 2497-2503
  CrossrefPubMedGoogle Scholar
• 356 Kaufman E, Lamster IB. The diagnostic applications of saliva – a review. Crit Rev Oral Biol Med 2002; 13: 197-212
  CrossrefPubMedGoogle Scholar
• 357 Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 243-254
  CrossrefPubMedGoogle Scholar
• 358 Kemp DE, Ganocy SJ, Brecher M et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011; 130: 171-179
  CrossrefPubMedGoogle Scholar
• 359 Kennedy MC. Post mortem drug concentrations. Intern Med J 2010; 40: 183-187
  CrossrefPubMedGoogle Scholar
• 360 Kerr BM, Thummel KE, Wurden CJ et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-1979
  CrossrefPubMedGoogle Scholar
• 361 Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57: 540-544
  CrossrefPubMedGoogle Scholar
• 362 Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best?. Clin Pharmacol Ther 2008; 83: 225-227
  CrossrefPubMedGoogle Scholar
• 363 Kirchheiner J, Meineke I, Müller G et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571-580
  CrossrefPubMedGoogle Scholar
• 364 Kirchheiner J, Müller G, Meineke I et al. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459-466
  CrossrefPubMedGoogle Scholar
• 365 Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473
  CrossrefPubMedGoogle Scholar
• 366 Kirchherr H, Kühn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B 2006; 843: 100-113
  CrossrefPubMedGoogle Scholar
• 367 Kirkton C, McIntyre IM. Therapeutic and toxic concentrations of mirtazapine. J Anal Toxicol 2006; 30: 687-691
  PubMedGoogle Scholar
• 368 Kirschbaum KM, Müller MJ, Malevani J et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008; 9: 212-218
  CrossrefPubMedGoogle Scholar
• 369 Kirschbaum KM, Müller MJ, Zernig G et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem 2005; 51: 1718-1721
  CrossrefPubMedGoogle Scholar
• 370 Kirschbaum KM, Uhr M, Holthoewer D et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59: 474-479
  CrossrefPubMedGoogle Scholar
• 371 Kjolbye M, Thomsen K, Rogne T et al. Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients. Ther Drug Monit 1994; 16: 541-547
  CrossrefPubMedGoogle Scholar
• 372 Klamerus KJ, Maloney K, Rudolph RL et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-724
  PubMedGoogle Scholar
• 373 Klampfl K, Taurines R, Preuss A et al. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 2010; 43: 58-65
  Article in Thieme ConnectPubMedGoogle Scholar
• 374 Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76
  CrossrefPubMedGoogle Scholar
• 375 Koepp MJ, Patsalos PN, Sander JW. Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Res 2002; 50: 277-282
  CrossrefPubMedGoogle Scholar
• 376 Kondo T, Otani K, Ishida M et al. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 1994; 16: 120-124
  CrossrefPubMedGoogle Scholar
• 377 Koostra-Ros JE, Van Weelden MJ, Hinrichs JW et al. Therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice. J Clin Pharmacol 2006; 46: 1320-1327
  PubMedGoogle Scholar
• 378 Kornhuber J, Quack G, Danysz W et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34: 713-721
  CrossrefPubMedGoogle Scholar
• 379 Koyama E, Chiba K, Tani M et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278: 21-30
  PubMedGoogle Scholar
• 380 Kozer E, Parvez S, Minassian BA et al. How high can we go with phenytoin?. Ther Drug Monit 2002; 24: 386-389
  CrossrefPubMedGoogle Scholar
• 381 Krska J, Corner DA. Serum drug level monitoring in affective disorders. J Clin Pharm Ther 1992; 17: 357-363
  CrossrefPubMedGoogle Scholar
• 382 Kugelberg FC, Druid H, Carlsson B et al. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. J Analyt Toxicol 2004; 28: 631-637
  PubMedGoogle Scholar
• 383 Kuhlman JJJR, Levine B, Johnson RE et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549-559
  PubMedGoogle Scholar
• 384 Kuss HJ, Feistenauer E. Quantitative high-performance liquid chromatographic assay for the determination of maprotiline and oxaprotiline in human plasma. J Chromatogr 1981; 204: 349-353
  CrossrefPubMedGoogle Scholar
• 385 Kvist EE, Al-Shurbaji A, Dahl ML et al. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin Pharmacokinet 2001; 40: 869-877
  CrossrefPubMedGoogle Scholar
• 386 Lappenberg-Pelzer M. Identification and determination of opipramol metabolites in plasma and urine. J Anal Toxicol 1998; 22: 215-219
  PubMedGoogle Scholar
• 387 Lautala P, Ethell BT, Taskinen J et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2000; 28: 1385-1389
  PubMedGoogle Scholar
• 388 Le Bloch Y, Woggon B, Weissenrieder H et al. Routine therapeutic drug monitoring in patients treated with 10–360 mg/day citalopram. Ther Drug Monit 2003; 25: 600-608
  CrossrefPubMedGoogle Scholar
• 389 Lee CA, Cook JA, Reyner EL et al. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 2010; 6: 603-619
  CrossrefPubMedGoogle Scholar
• 390 Lee SY, Kim YG, Kim HG et al. Pharmacokineitc parameters of bromperidol in Korean subjects. Hum Psychopharmacol 2006; 21: 409-412
  CrossrefPubMedGoogle Scholar
• 391 Lefèvre G, Büche M, Sedek G et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 2009; 49: 430-443
  PubMedGoogle Scholar
• 392 Leucht S, Busch R, Kissling W et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 68: 352-360
  Google Scholar
• 393 Leucht S, Steimer W, Kreuz S et al. Doxepin plasma concentrations: is there really a therapeutic range?. J Clin Psychopharmacol 2001; 21: 432-439
  CrossrefPubMedGoogle Scholar
• 394 LeWitt PA, Jennings D, Kelly EL et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009; 24: 1319-1324
  CrossrefPubMedGoogle Scholar
• 395 Licht RW, Vestergaard P, Kessing LV et al. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003; 419: 1-22
  PubMedGoogle Scholar
• 396 Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med 2005; 353: 1209-1223
  Google Scholar
• 397 Lind AB, Reis M, Bengtsson F et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 2009; 48: 63-70
  CrossrefPubMedGoogle Scholar
• 398 Lindberger M, Luhr O, Johannessen SI et al. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit 2003; 25: 457-462
  CrossrefPubMedGoogle Scholar
• 399 Lindenmayer J. Long-acting injectable antipsychotics: focus on Olanzapine pamoate. Neuropsychiatr Dis Treat 2010; 6: 261-267
  PubMedGoogle Scholar
• 400 Linder MW, Keck PEJR. Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998; 44: 1073-1084
  PubMedGoogle Scholar
• 401 Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002; 105: 164-172
  CrossrefPubMedGoogle Scholar
• 402 Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
  PubMedGoogle Scholar
• 403 Liu Y, Jiao J, Zhang C et al. A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. Biol Pharm Bull 2009; 32: 717-720
  CrossrefPubMedGoogle Scholar
• 404 Liu ZQ, Shu Y, Huang SL et al. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin 2001; 22: 85-90
  PubMedGoogle Scholar
• 405 Lobo ED, Bergstrom RF, Reddy S et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008; 47: 191-202
  CrossrefPubMedGoogle Scholar
• 406 Locatelli I, Kstelic M. Kores-Plesnicar et al. A population pharmacokinetic evalutation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode schizophrenia. Eur J Pharm Sci 2010; 41: 289-298
  CrossrefPubMedGoogle Scholar
• 407 Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005; 45: 1106-1122
  CrossrefPubMedGoogle Scholar
• 408 Lucek R, Dixon R. Chlordiazepoxide concentrations in saliva and plasma measured by radioimmunoassay. Res Commun Chem Pathol Pharmacol 1980; 27: 397-400
  PubMedGoogle Scholar
• 409 Lundberg J, Christophersen JS, Petereson KB et al. Int J Neuropsychopharmacol 2007; 10: 777-785
  PubMed
• 410 Lundmark J, Bengtsson F, Nordin C et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354-359
  CrossrefPubMedGoogle Scholar
• 411 Luurila H, Olkkola KT. Pharmacokinetic-pharmacodynamic modelling of zopiclione effects on human central nervous system. Pharmacol Toxicol 1996; 78: 348-353
  CrossrefPubMedGoogle Scholar
• 412 Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22: 1212-1219
  PubMedGoogle Scholar
• 413 Madsen H, Nielsen KK, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms – a population study. Br J Clin Pharmacol 1995; 39: 433-439
  CrossrefPubMedGoogle Scholar
• 414 Maguire KP, Burrows GD, Norman TR et al. Metabolism and pharmacokinetics of dothiepin. Br J Clin Pharmacol 1981; 12: 405-409
  CrossrefPubMedGoogle Scholar
• 415 Maguire KP, Norman TR, Burrows GD et al. An evaluation of maprotiline intravenous kinetics and comparison of two oral doses. Eur J Clin Pharmacol 1980; 18: 249-254
  CrossrefPubMedGoogle Scholar
• 416 Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999; 36: 277-287
  CrossrefPubMedGoogle Scholar
• 417 Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44: 179-187
  PubMedGoogle Scholar
• 418 Mamo D, Kapur S, Keshavan M et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008; 33: 298-304
  CrossrefPubMedGoogle Scholar
• 419 Mamo D, Kapur S, Shammi CM et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161: 818-825
  CrossrefPubMedGoogle Scholar
• 420 Mann K, Hiemke C, Lotz J et al. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol 2006; 26: 671-673
  CrossrefPubMedGoogle Scholar
• 421 Mann K, Hiemke C, Schmidt LG et al. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 2006; 28: 83-88
  CrossrefPubMedGoogle Scholar
• 422 Markowitz J, Patrick K. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?. J Clin Psychopharmacol 2008; 28 (Suppl. 02) S54-S61
  CrossrefPubMedGoogle Scholar
• 423 Martines C, Gatti G, Sasso E et al. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990; 30: 607-611
  CrossrefPubMedGoogle Scholar
• 424 Mason BJ, Goodman AM, Dixon RM et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27: 596-606
  Google Scholar
• 425 Mattila MA, Larni HM. Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs 1980; 20: 353-374
  CrossrefPubMedGoogle Scholar
• 426 Mauri MC, Laini V, Boscati L et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001; 16: 57-63
  CrossrefPubMedGoogle Scholar
• 427 Mauri MC, Volonteri LS, Colasanti A et al. Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359-388
  CrossrefPubMedGoogle Scholar
• 428 May TW, Korn-Merker E, Rambeck B.. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023-1042
  CrossrefPubMedGoogle Scholar
• 429 May TW, Korn-Merker E, Rambeck B et al. Pharmacokinetics of sulthiame in epileptic patients. Ther Drug Monit 1994; 16: 251-257
  CrossrefPubMedGoogle Scholar
• 430 May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003; 25: 690-699
  CrossrefPubMedGoogle Scholar
• 431 May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 2002; 24: 366-374
  CrossrefPubMedGoogle Scholar
• 432 May TW, Rambeck B, Neb R et al. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2007; 29: 789-794
  CrossrefPubMedGoogle Scholar
• 433 Mayo BC, Biggs SR, Chasseaud LF et al. The metabolic fate of Sormodren (bornaprine hydrochloride) in animals and humans. Xenobiotica 1980; 10: 873-888
  CrossrefPubMedGoogle Scholar
• 434 McAlpine DE, Biernacka JM, Mrazek DA et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33: 14-20
  CrossrefPubMedGoogle Scholar
• 435 McConville BJ, Arvanitis LA, Thyrum PT et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61: 252-260
  CrossrefPubMedGoogle Scholar
• 436 McKenzie ME, Roswell-Harris D. A controlled trial of prothipendyl (tolnate) in mentally subnormal patients. Br J Psychiatry 1966; 112: 95-100
  CrossrefPubMedGoogle Scholar
• 437 Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 2006; 16: 233-240
  CrossrefPubMedGoogle Scholar
• 438 Mehler-Wex C, Kölch M, Kirchheiner J et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 2009; 3: 14
  CrossrefPubMedGoogle Scholar
• 439 Meijer WE, Bouvy ML, Heerdink ER et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 179: 519-522
  CrossrefPubMedGoogle Scholar
• 440 Meineke I, Kress I, Poser W et al. Therapeutic drug monitoring and its metabolite desmethylmirtazapine by HPLC with fluorescence detection. Ther Drug Monit 2004; 26: 277-283
  CrossrefPubMedGoogle Scholar
• 441 Meisenzahl EM, Schmitt G, Gründer G et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008; 41: 169-175
  Article in Thieme ConnectPubMedGoogle Scholar
• 442 Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86-102
  PubMedGoogle Scholar
• 443 Meyer JH, Wilson AA, Sagrati S et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [¹¹C]DASB positron emission tomography study. Am J Psychiatry 2004; 161: 826-835
  CrossrefPubMedGoogle Scholar
• 444 Meyer RP, Gehlhaus M, Knoth R et al. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 2007; 8: 297-306
  CrossrefPubMedGoogle Scholar
• 445 Meyer-Barner M, Meineke I, Schreeb KH et al. Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol 2002; 58: 253-257
  CrossrefPubMedGoogle Scholar
• 446 Michelson D, Read HA, Ruff DD et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242-251
  CrossrefPubMedGoogle Scholar
• 447 Mihara K, Yasui-Furukori N, Kondo T et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 2002; 24: 563-566
  CrossrefPubMedGoogle Scholar
• 448 Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-597
  CrossrefPubMedGoogle Scholar
• 449 Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure 2004; 13 (Suppl. 01) S17-S23
  CrossrefPubMedGoogle Scholar
• 450 Miura M, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica 2007; 37: 169-179
  CrossrefPubMedGoogle Scholar
• 451 Moffat AC. editor Clarke’s analysis of drugs and poisons. London: Pharmaceutical Press; 2003: 1468-1469
• 452 Molden E, Lunde H, Lunder N et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazone in psychiatric patients. Ther Drug Monit 2006; 28: 744-749
  CrossrefPubMedGoogle Scholar
• 453 Montgomery SA, McAuley R, Montgomery DB. Relationsship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. Br J Clin Pharmacol 1978; 5: 71S-76S
  CrossrefPubMedGoogle Scholar
• 454 Moody DE, Chang Y, Huang W et al. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol 2009; 105: 211-215
  CrossrefPubMedGoogle Scholar
• 455 Morris RG, Black AB, Harris AL et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998; 46: 547-551
  PubMedGoogle Scholar
• 456 Morris RG, Lee MY, Cleanthous X et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 2004; 26: 626-632
  CrossrefPubMedGoogle Scholar
• 457 Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci 2010; 12: 69-76
  PubMedGoogle Scholar
• 458 Müller H, Eusterschulte B, Havemann-Reinecke U et al. Forensische Aspekte des therapeutischen Drug-Monitorings (TDM) in der Psychiatrie. Psychopharmakotherapie 2009; 16: 52-56
  PubMedGoogle Scholar
• 459 Müller MJ, Dragicevic A, Fric M et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?. Pharmacopsychiatry 2003; 36: 98-104
  Article in Thieme ConnectPubMedGoogle Scholar
• 460 Müller MJ, Härtter S, Köhler D et al. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. Pharmacopsychiatry 2001; 34: 27-32
  Article in Thieme ConnectPubMedGoogle Scholar
• 461 Müller MJ, Regenbogen B, Härtter S et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiat Res 2007; 41: 673-679
  CrossrefPubMedGoogle Scholar
• 462 Müller-Isberner R, Freese R, Jöckel D et al. Forensic psychiatric assessment and treatment in Germany. Legal framework, recent developments, and current practice. Int J Law Psychiatry 2000; 23: 467-480
  CrossrefPubMedGoogle Scholar
• 463 Nagy CF, Kumar D, Cullen EI et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004; 58 (Suppl. 01) 18-24
  CrossrefPubMedGoogle Scholar
• 464 Naito H, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol Scand 1987; 76: 58-63
  CrossrefPubMedGoogle Scholar
• 465 Nakamura K, Yokoi T, Inoue K et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996; 6: 449-457
  CrossrefPubMedGoogle Scholar
• 466 Nazirizadeh Y, Vogel F, Bader W et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 2010; 66: 797-803
  CrossrefPubMedGoogle Scholar
• 467 Neels HM, Sierens AC, Naelaerts K et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin chem Lab Med 2004; 42: 1228-1255
  CrossrefPubMedGoogle Scholar
• 468 Nemoda Z, Angyal N, Tarnok Z et al. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 2009; 57: 731-733
  CrossrefPubMedGoogle Scholar
• 469 Nesvag R, Hendset M, Refsum H et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006; 114: 21-26
  CrossrefPubMedGoogle Scholar
• 470 Nikisch G, Baumann P, Oneda B et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2010; Dec 8 [Epub ahead of print]
  PubMedGoogle Scholar
• 471 Nikisch G, Mathé AA, Czernik A et al. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 2004; 24: 283-290
  CrossrefPubMedGoogle Scholar
• 472 Nikolaus S, Larisch R, Beu M et al. In vivo measurement of D2 receptor density and affinity for 18F-(3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals. J Nucl Med 2003; 44: 618-624
  PubMedGoogle Scholar
• 473 Nilsen OG, Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol 1992; 71: 150-153
  CrossrefPubMedGoogle Scholar
• 474 Nilsson MI, Meresaar U, Ånggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand Suppl 1982; 74: 66-69
  PubMedGoogle Scholar
• 475 Nishikage H, Nakanishi T, Takamitsu Y et al. Sequential changes in the plasma concentration of risperidone following intentional overdose. Clin Neuropharmacol 2002; 25: 307-309
  CrossrefPubMedGoogle Scholar
• 476 Nnadi CU, Malhotra AK. Clinical and pharmacogenetic studies of iloperidone. Per Med 2008; 5: 367-375
  CrossrefPubMedGoogle Scholar
• 477 Norman T, Chiu E, James RH et al. Single oral dose pharmacokinetics of tiapride in patients with Huntington’s disease. Eur J Clin Pharmacol 1987; 32: 583-586
  CrossrefPubMedGoogle Scholar
• 478 Nozawa M, Ohnuma T, Matsubara Y et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics. Ther Drug Monit 2008; 30: 35-40
  CrossrefPubMedGoogle Scholar
• 479 Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35-49
  CrossrefPubMedGoogle Scholar
• 480 Nyberg S, Nordström AL, Halldin C et al. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 1995; 10 (Suppl. 03) 81-85
  PubMedGoogle Scholar
• 481 Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006; 45: 109-136
  CrossrefPubMedGoogle Scholar
• 482 Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33: 262-270
  PubMedGoogle Scholar
• 483 Öhman D, Cherma MD, Norlander B et al. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit 2003; 25: 174-182
  CrossrefPubMedGoogle Scholar
• 484 Öhman D, Norlander B, Peterson C et al. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC. Ther Drug Monit 2001; 23: 27-34
  CrossrefPubMedGoogle Scholar
• 485 Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25: 740-744
  PubMedGoogle Scholar
• 486 Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50: 563-571
  PubMedGoogle Scholar
• 487 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
  CrossrefPubMedGoogle Scholar
• 488 Orsulak PJ. Therapeutic monitoring of antidepressant drugs: current methodology and applications. J Clin Psychiatry 1986; 47 (Suppl) 39-52
  PubMedGoogle Scholar
• 489 Orsulak PJ. Therapeutic monitoring of antidepressant drugs: guidelines updated. Ther Drug Monit 1989; 11: 497-507
  CrossrefPubMedGoogle Scholar
• 490 Orsulak PJ, Schildkraut JJ. Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels. Ther Drug Monit 1979; 1: 199-208
  CrossrefPubMedGoogle Scholar
• 491 Ostad Haji E, Tadić A, Wagner S et al. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol 2011; 31: 281-286
  CrossrefPubMedGoogle Scholar
• 492 Ota T, Shinotoh H, Fukushi K et al. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer’s disease using positron emission tomography. Clin Neuropharmacol 2010; 33: 74-78
  CrossrefPubMedGoogle Scholar
• 493 Palego L, Biondi L, Giannaccini G et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 473-480
  CrossrefPubMedGoogle Scholar
• 494 Panagiotidis G, Arthur HW, Lindh JD et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 2007; 29: 417-422
  CrossrefPubMedGoogle Scholar
• 495 Paris BL, Ogilvie BW, Scheinkoenig JA et al. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 2009; 37: 2045-2054
  CrossrefPubMedGoogle Scholar
• 496 Park JY, Kim KA, Park PW et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006; 79: 590-599
  CrossrefPubMedGoogle Scholar
• 497 Park PW, Seo YH, Ahn JY et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34: 569-574
  CrossrefPubMedGoogle Scholar
• 498 Parker DR, McIntyre IM. Case studies of post-mortem quetiapine: therapeutic or toxic concentrations?. J Analyt Toxicol 2005; 29: 407-412
  PubMedGoogle Scholar
• 499 Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276
  CrossrefPubMedGoogle Scholar
• 500 Paz E, Bouzas L, Hermida J et al. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem 2008; 41: 603-606
  CrossrefPubMedGoogle Scholar
• 501 Pearce GA, Day RO. Compliance with criteria necessary for effective drug concentration monitoring. Ther Drug Monit 1990; 12: 250-257
  CrossrefPubMedGoogle Scholar
• 502 Pedersen OL, Gram LF, Kristensen CB et al. Overdosage of Antidepressants: Clinical and Pharmacokinetic Aspects. Eur J Clin Pharmacol 1982; 23: 513-521
  CrossrefPubMedGoogle Scholar
• 503 Perez J, Chiron C, Musial C et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40: 1618-1626
  CrossrefPubMedGoogle Scholar
• 504 Perry PJ. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13: 381-392
  CrossrefPubMedGoogle Scholar
• 505 Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 2001; 35: 19-29
  PubMedGoogle Scholar
• 506 Perry PJ, Browne JL, Alexander B et al. Relationship of free nortriptyline levels to therapeutic response. Acta Psychiatr Scand 1985; 72: 120-125
  CrossrefPubMedGoogle Scholar
• 507 Perry PJ, Miller DD, Arndt SV et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235
  PubMedGoogle Scholar
• 508 Perry PJ, Miller DD, Arndt SV et al. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharmacol 1993; 13: 46-51
  PubMedGoogle Scholar
• 509 Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely III schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472-477
  CrossrefPubMedGoogle Scholar
• 510 Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230-240
  PubMedGoogle Scholar
• 511 Perucca E, Cloyd J, Critchley D et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-1141
  CrossrefPubMedGoogle Scholar
• 512 Petit P, Lonjon R, Cociglio M et al. Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates. Eur J Clin Pharmacol 1991; 41: 541-546
  CrossrefPubMedGoogle Scholar
• 513 Peyronneau MA, Delaforge M, Riviere R et al. High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur J Biochem 1994; 223: 947-956
  CrossrefPubMedGoogle Scholar
• 514 Pichini S, Papaseit E, Joya X et al. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit 2009; 31: 283-318
  CrossrefPubMedGoogle Scholar
• 515 Pierce DM, Franklin RA, Harry TV et al. Pharmacodynamic correlates of modified absorption: studies with lormetazepam. Br J Clin Pharmacol 1984; 18: 31-35
  CrossrefPubMedGoogle Scholar
• 516 Poggesi I, Benedetti MS, Whomsley R et al. Pharmacokinetics in special populations. Drug Metab Rev 2009; 41: 422-454
  CrossrefPubMedGoogle Scholar
• 517 Potgieter GE, Groenewoud G, Jordaan PJ et al. Pharmacokinetics of pipamperone from three different tablet formulations. Arzneimittelforschung 2002; 52: 430-444
  Article in Thieme ConnectPubMedGoogle Scholar
• 518 Pounder DJ, Jones GR. Post-mortem drug redistribution – a toxicological nightmare. Forensic Sci Int 1990; 45: 253-263
  CrossrefPubMedGoogle Scholar
• 519 Prakash C, Kamel A, Cui D et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 (Suppl. 01) 35S-42S
  PubMedGoogle Scholar
• 520 Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenafaxine in extensive and poor cytochrome P450 metabolizers. J Clin Psychopharmacol 2009; 29: 39-43
  CrossrefPubMedGoogle Scholar
• 521 Preskorn SH. CNS drug development: part I: the early period of CNS drugs. J Psychiatr Pract 2010; 16: 334-339
  CrossrefPubMedGoogle Scholar
• 522 Preskorn SH. CNS drug development: Part II: Advances from the 1960s to the 1990s. J Psychiatr Pract 2010; 16: 413-415
  CrossrefPubMedGoogle Scholar
• 523 Preskorn SH. Patients who do not respond to the “usual” dose: why Terry fell off the dose-response curve. J Psychiatr Pract 2009; 15: 460-466
  CrossrefPubMedGoogle Scholar
• 524 Preskorn SH. Practical application of therapeutic drug monitoring: a tale of two patients. J Psychiatr Pract 2008; 14: 301-306
  CrossrefPubMedGoogle Scholar
• 525 Preskorn SH. Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach. J Clin Psychiatry 1986; 47 (Suppl. 01) 24-30
  PubMedGoogle Scholar
• 526 Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: Principles and practice. Ther Drug Monit 1993; 16: 611-641
  PubMedGoogle Scholar
• 527 Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiat 1991; 52 (Suppl) 23-33
  PubMedGoogle Scholar
• 528 Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160-162
  PubMedGoogle Scholar
• 529 Preskorn SH, Fleck RJ, Schroeder DH. Therapeutic drug monitoring of bupropion. Am J Psychiatry 1990; 147: 1690-1691
  PubMedGoogle Scholar
• 530 Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10: 88-95
  CrossrefPubMedGoogle Scholar
• 531 Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatr Scand 1998; 98: 65-72
  CrossrefPubMedGoogle Scholar
• 532 Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008; 13: 511-514
  PubMedGoogle Scholar
• 533 Puozzo C, Albin H, Vinçon G et al. Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 1998; 23: 273-279
  CrossrefPubMedGoogle Scholar
• 534 Raaflaub J. On the pharmacokinetics of chlorprothixene in man. Experientia 1975; 31: 557-558
  CrossrefPubMedGoogle Scholar
• 535 Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001; 42 (Suppl. 04) 24-27
  PubMedGoogle Scholar
• 536 Rao VA, Bishop M, Coppen A. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry 1980; 137: 518-521
  CrossrefPubMedGoogle Scholar
• 537 Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. Ther Drug Monit 2000; 22: 143-154
  CrossrefPubMedGoogle Scholar
• 538 Rasmussen PV, Jensen TS, Sindrup SH et al. TDM-based imipramine treatment in neuropathic pain. Ther Drug Monit 2004; 26: 352-360
  CrossrefPubMedGoogle Scholar
• 539 Rauschenbach R, Gieschen H, Husemann M et al. Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol 1995; 293: 183-190
  CrossrefPubMedGoogle Scholar
• 540 Ravva P, Gastonguay MR, Tensfeldt TG et al. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 2009; 68: 669-681
  CrossrefPubMedGoogle Scholar
• 541 Rees JA. Clinical interpretation of pharmacokinetic data on dothiepine hydrochloride (Dosulepin, Prothiaden). J Int Med Res 1981; 9: 98-102
  PubMedGoogle Scholar
• 542 Regenthal R, Krueger M, Koeppel C et al. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 1999; 15: 529-544
  CrossrefPubMedGoogle Scholar
• 543 Reimold M, Solbach C, Noda S et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 2007; 190: 241-249
  PubMedGoogle Scholar
• 544 Reis M, Aamo T, Ahlner J et al. Reference concentrations of antidepressants. A compilation of post-mortem and therapeutic levels. J Analyt Toxicol 2007; 31: 254-264
  PubMedGoogle Scholar
• 545 Reis M, Aamo T, Spigset O et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009; 31: 42-56
  CrossrefPubMedGoogle Scholar
• 546 Reis M, Åberg-Wistedt A, Ågren H et al. Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disorders 2004; 82: 443-446
  PubMedGoogle Scholar
• 547 Reis M, Akerblad AC, Ekselius L et al. Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care. J Clin Psychopharmacol 2010; 30: 746-748
  CrossrefPubMedGoogle Scholar
• 548 Reis M, Chermá MD, Carlsson B et al. On behalf of the task force for TDM of escitalopram in Sweden. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 2007; 29: 758-766
  CrossrefPubMedGoogle Scholar
• 549 Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997. Ther Drug Monit 2003; 25: 183-191
  CrossrefPubMedGoogle Scholar
• 550 Reis M, Lundmark J, Björk H et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002; 24: 545-553
  CrossrefPubMedGoogle Scholar
• 551 Reis M, Olsson G, Carlsson B et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002; 22: 406-413
  CrossrefPubMedGoogle Scholar
• 552 Reis M, Prochazka J, Sitsen A et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit 2005; 27: 469-477
  CrossrefPubMedGoogle Scholar
• 553 Remington G, Mamo D, Labelle A et al. A PET study evaluating dopamine D₂ receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006; 163: 396-401
  CrossrefPubMedGoogle Scholar
• 554 Renwick AB, Mistry H, Ball SE et al. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28: 337-348
  CrossrefPubMedGoogle Scholar
• 555 Riant P, Urien S, Albengres E et al. Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier. J Neurochem 1988; 51: 421-425
  CrossrefPubMedGoogle Scholar
• 556 Richens A, Banfield CR, Salfi M et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997; 44: 129-134
  CrossrefPubMedGoogle Scholar
• 557 Riedel M, Schwarz MJ, Strassnig M et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosi 2005; 255: 261-268
  PubMedGoogle Scholar
• 558 Rivas N, Buelga DS, Elger CE et al. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 2008; 30: 483-489
  PubMedGoogle Scholar
• 559 Rivera-Calimlim L, Castañeda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 1973; 14: 978-986
  PubMedGoogle Scholar
• 560 Roberts RL, Joyce PR, Mulder RT et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191-196
  CrossrefPubMedGoogle Scholar
• 561 Robertson PJR, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42: 123-137
  CrossrefPubMedGoogle Scholar
• 562 Rochat B, Kosel M, Boss G et al. Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 1998; 56: 15-23
  CrossrefPubMedGoogle Scholar
• 563 Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303
  PubMedGoogle Scholar
• 564 Roman M, Kronstrand R, Lindstedt D et al. Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS. J Anal Toxicol 2008; 32: 147-155
  PubMedGoogle Scholar
• 565 Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 (Suppl. 01) 22-30
  CrossrefPubMedGoogle Scholar
• 566 Rosenzweig P, Canal M, Patat A et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 2002; 17: 1-13
  CrossrefPubMedGoogle Scholar
• 567 Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26: 572-575
  PubMedGoogle Scholar
• 568 Rougemont M, Ulrich S, Hiemke C et al. French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. Fundam Clin Pharmacol 2010; 24: 377-384
  CrossrefPubMedGoogle Scholar
• 569 Rudorfer V, Potter WZ. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 1997; 7: 273-312
  CrossrefPubMedGoogle Scholar
• 570 Ruottinen HM, Rinne UK. Effect of one month’s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996; 19: 222-233
  CrossrefPubMedGoogle Scholar
• 571 Sachse J, Härtter S, Hiemke C. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. Ther Drug Monit 2005; 27: 158-162
  CrossrefPubMedGoogle Scholar
• 572 Sachse J, Härtter S, Weigmann H et al. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 405-410
  PubMedGoogle Scholar
• 573 Sachse J, Köller J, Härtter S et al. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 342-348
  PubMedGoogle Scholar
• 574 Sagar KA, Smyth MR. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. Analyst 2000; 125: 439-445
  CrossrefPubMedGoogle Scholar
• 575 Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa. Clin Neuropharmacol 1994; 17 (Suppl. 02) 1-6
  CrossrefPubMedGoogle Scholar
• 576 Sainati SM, Hubbard JW, Chi E et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995; 35: 713-720
  PubMedGoogle Scholar
• 577 Saint-Marcoux F, Sauvage FL, Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 2007; 388: 1327-1349
  CrossrefPubMedGoogle Scholar
• 578 Saivin S, Hulot T, Chabac S et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998; 35: 331-345
  CrossrefPubMedGoogle Scholar
• 579 Sajatovic M, Velligan DI, Weiden PJ et al. Measurement of psychiatric treatment adherence. J Psychosom Res 2010; 69: 591-599
  CrossrefPubMedGoogle Scholar
• 580 Salazar DE, Frackiewicz EJ, Dockens R et al. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. J Clin Pharmacol 2001; 41: 1351-1358
  PubMedGoogle Scholar
• 581 Sallee FR, Pollock BG, Stiller RL et al. Pharmacokinetics of pimozide in adults and children with Tourette’s syndrome. J Clin Pharmacol 1987; 27: 776-781
  PubMedGoogle Scholar
• 582 Sartorius N, Baghai TC, Baldwin DS et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 2007; 10 (Suppl. 01) S1-S207
  CrossrefPubMedGoogle Scholar
• 583 Sauer JM, Ring BJ, Witcher JW. Clinical Pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005; 44: 571-590
  CrossrefPubMedGoogle Scholar
• 584 Sauvage FL, Gaulier JM, Lachâtre G et al. Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. Clin Chem 2008; 54: 1519-1527
  CrossrefPubMedGoogle Scholar
• 585 Schulberg HC, Katon W, Simon GE et al. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55: 1121-1127
  CrossrefPubMedGoogle Scholar
• 586 Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003; 58: 447-474
  PubMedGoogle Scholar
• 587 Schwarzenbach F, Netillard C, Demoly P et al. Antidepressant response and fluvoxamine plasma concentrations: a pilot study. Pharm World Sci 2003; 25: 27-29
  CrossrefPubMedGoogle Scholar
• 588 Scordo MG, Spina E, Dahl ML et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97: 296-301
  CrossrefPubMedGoogle Scholar
• 589 Seiler W, Wetzel H, Hillert A et al. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology (Berl) 1994; 116: 457-463
  CrossrefPubMedGoogle Scholar
• 590 Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008; 46: 71-73
  CrossrefPubMedGoogle Scholar
• 591 Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit 2004; 26: 78-84
  CrossrefPubMedGoogle Scholar
• 592 Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31: 493-502
  CrossrefPubMedGoogle Scholar
• 593 Sharma S, Joshi S, Chadda RK. Therapeutic drug monitoring of lithium in patients with bipolar affective disorder: experiences from a tertiary care hospital in India. Am J Ther 2009; 16: 393-397
  CrossrefPubMedGoogle Scholar
• 594 Shin JG, Soukova N, Flockart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27: 1078-1084
  PubMedGoogle Scholar
• 595 Shinderman M, Maxwell S, Brawand-Amey M et al. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003; 69: 205-211
  CrossrefPubMedGoogle Scholar
• 596 Shiraga T, Kaneko H, Iwasaki K et al. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999; 29: 217-229
  CrossrefPubMedGoogle Scholar
• 597 Shua-Haim J, Smith J, Picard F et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig 2008; 28: 361-374
  PubMedGoogle Scholar
• 598 Sidhu J, Priskorn M, Poulsen M et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in human. Chirality 1997; 9: 686-692
  CrossrefPubMedGoogle Scholar
• 599 Siva N. Tackling the booming trade in counterfeit drugs. Lancet 2010; 376: 1725-1726
  CrossrefPubMedGoogle Scholar
• 600 Skinner MH, Kuan HY, Skerjanec A et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004; 57: 54-61
  PubMedGoogle Scholar
• 601 Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999; 21: 580-582
  CrossrefPubMedGoogle Scholar
• 602 Skogh E, Reis M, Dahl ML et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002; 24: 518-526
  CrossrefPubMedGoogle Scholar
• 603 Small JG, Hirsch SR, Arvanitis LA et al. Quetiapine in patients with schizophrenia – a high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiatry 1997; 54: 549-557
  PubMedGoogle Scholar
• 604 Smith RB, Kroboth PD, Vanderlugt JT et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl) 1984; 84: 452-456
  CrossrefPubMedGoogle Scholar
• 605 Smith SW. Chiral toxicology: it’s the same thing…only different. Toxicol Sci 2009; 110: 4-30
  CrossrefPubMedGoogle Scholar
• 606 Snoeck E, Van Peer A, Sack M et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995; 122: 223-229
  CrossrefPubMedGoogle Scholar
• 607 Søgaard B, Mengel H, Rao N et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005; 45: 1400-1406
  PubMedGoogle Scholar
• 608 Soldin P, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48: 143-157
  CrossrefPubMedGoogle Scholar
• 609 Someya T, Muratake T, Hirokane G et al. Interindividual variation in bromperidl metabolism and relationship to therapeutic effects. J Clin Psychopharmacol 2000; 20: 175-180
  CrossrefPubMedGoogle Scholar
• 610 Søndergaard Khinchi M, Nielsen KA, Dahl M et al. Lamotrigine therapeutic thresholds. Seizure 2008; 17: 391-395
  CrossrefPubMedGoogle Scholar
• 611 Soni SD. Fluspirilene in the treatment of non-hospitalized schizophrenic patients. Curr Med Res Opin 1977; 4: 645-649
  CrossrefPubMedGoogle Scholar
• 612 Sparshatt A, Taylor D, Patel MX et al. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010; 71: 1447-1456
  CrossrefPubMedGoogle Scholar
• 613 Sparshatt A, Taylor D, Patel MX et al. Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009; 120: 416-428
  CrossrefPubMedGoogle Scholar
• 614 Spencer TJ, Biederman J, Ciccone PE et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006; 163: 387-395
  CrossrefPubMedGoogle Scholar
• 615 Spencer TJ, Bonab AA, Dougherty DD et al. A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. Int J Mol Med 2010; 25: 261-265
  PubMedGoogle Scholar
• 616 Spigset O, Hägg S, Stegmayr B et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 59: 699-703
  PubMedGoogle Scholar
• 617 Spina E, Avenoso A, Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001; 153: 238-243
  CrossrefPubMedGoogle Scholar
• 618 Spina E, Birgersson C, von Bahr Ö et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984; 36: 677-682
  CrossrefPubMedGoogle Scholar
• 619 Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16: 165-177
  CrossrefPubMedGoogle Scholar
• 620 Stassen HH, Anghelescu IG, Angst J et al. Predicting response to psychopharmacological treatment. Survey of recent results. Pharmacopsychiatry 2011; 44: 263-272
  Article in Thieme ConnectPubMedGoogle Scholar
• 621 Stassen HH, Angst J, Hell D et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68: 1195-1205
  CrossrefPubMedGoogle Scholar
• 622 Stead AH, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Exp Toxicol 1983; 3: 437-464
  PubMedGoogle Scholar
• 623 Steimer W. Pharmacogenetics and Psychoactive Drug Therapy: Ready for the Patient?. Ther Drug Monit 2010; 32: 381-386
  CrossrefPubMedGoogle Scholar
• 624 Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315: 137-155
  CrossrefPubMedGoogle Scholar
• 625 Steimer W, Zöpf K, von Amelunxen S et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376-385
  CrossrefPubMedGoogle Scholar
• 626 Stieffenhofer V, Hiemke C. Pharmacogenetics, therapeutic drug monitoring and non compliance. Ther Umsch 2010; 67: 309-315
  CrossrefPubMedGoogle Scholar
• 627 Stieffenhofer V, Saglam H, Schmidtmann I et al. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry 2011; 44: 55-59
  Article in Thieme ConnectPubMedGoogle Scholar
• 628 Stock B, Spiteller G. Metabolism of antiparkinson drugs. An example of competitive hydroxylation. Arzneimittelforschung 1979; 29: 610-615
  PubMedGoogle Scholar
• 629 Störmer E, Brockmöller J, Roots I et al. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug in vitro. Psychopharmacology (Berl) 2000; 151: 312-320
  CrossrefPubMedGoogle Scholar
• 630 Störmer E, von Moltke LL, Shader RI et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28: 1168-1175
  PubMedGoogle Scholar
• 631 Suhara T, Takano A, Sudo Y et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003; 60: 386-391
  CrossrefPubMedGoogle Scholar
• 632 Sutfin TA, Perini GI, Molnar G et al. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 1988; 8: 48-53
  PubMedGoogle Scholar
• 633 Suzuki A, Otani K, Ishida M et al. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit 1997; 19: 261-264
  CrossrefPubMedGoogle Scholar
• 634 Suzuki Y, Fukui N, Sawamura K et al. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol 2008; 28: 325-328
  CrossrefPubMedGoogle Scholar
• 635 Svirbely JR, Speicher CE. The importance of request and report forms in the interpretation of therapeutic drug monitoring data. Ther Drug Monit 1980; 2: 211-216
  CrossrefPubMedGoogle Scholar
• 636 Sweet RA, Pollock BG, Kirshner M et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995; 35: 876-884
  PubMedGoogle Scholar
• 637 Sweet RA, Pollock BG, Mulsant BH et al. Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol 2000; 20: 181-187
  CrossrefPubMedGoogle Scholar
• 638 Szegedi A, Jansen WT, van Willigenburg AP et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70: 344-353
  CrossrefPubMedGoogle Scholar
• 639 Takano A, Suhara T, Ichimiya T et al. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol 2006; 26: 188-191
  CrossrefPubMedGoogle Scholar
• 640 Takano A, Suzuki K, Kosaka J et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology 2006; 185: 395-399
  CrossrefPubMedGoogle Scholar
• 641 Tan L, Yu JT, Sun YP et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010; 112: 320-323
  CrossrefPubMedGoogle Scholar
• 642 Tanaka O, Kondo T, Otani K et al. Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects. Ther Drug Monit 1998; 20: 117-119
  CrossrefPubMedGoogle Scholar
• 643 Tanaka E, Kurata N, Yasuhara H. How useful is the “cocktail approach” for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?. J Clin Pharm Ther 2003; 28: 157-165
  CrossrefPubMedGoogle Scholar
• 644 Tasker TCG, Kaye CM, Zussman BD et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989; 80 (350) 152-155
  CrossrefPubMedGoogle Scholar
• 645 Tateishi T, Watanabe M, Kumai T et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67: 2913-2920
  CrossrefPubMedGoogle Scholar
• 646 Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008; 118: 434-442
  CrossrefPubMedGoogle Scholar
• 647 Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl 2009; 52: S13-S19
  PubMedGoogle Scholar
• 648 Thanacoody RH, Daly AK, Reilly JG et al. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther 2007; 82: 555-565
  CrossrefPubMedGoogle Scholar
• 649 The Scottish Schizophrenia Research Group . The Scottish first episode Schizophrenia study II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 1987; 150: 334-338
  CrossrefPubMedGoogle Scholar
• 650 Thieme D, Rolf B, Sachs H et al. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med 2008; 122: 149-155
  CrossrefPubMedGoogle Scholar
• 651 Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461-474
  CrossrefPubMedGoogle Scholar
• 652 Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 (Suppl. 01) 13-18
  CrossrefPubMedGoogle Scholar
• 653 Titier K, Canal M, Déridet E et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004; 199: 52-60
  CrossrefPubMedGoogle Scholar
• 654 Toennes SW, Maurer HH. Microsoft Excel in pharmacokinetics – an easy way to solve kinetic problems in clinical toxicology, legal medicine or doping control. In Sachs H, Bernhard W, Jeger A. (eds.) Proceedings of the 34^th International TIAFT Meeting, Interlaken. 11–15 August 1996 Leipzig: Molina; 1997: 201-204
  Google Scholar
• 655 Tokairin T, Fukasawa T, Yasui-Furukori N et al. Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol 2005; 60: 172-175
  CrossrefPubMedGoogle Scholar
• 656 Tokunaga H, Kudo K, Imamura T et al. Plasma concentrations of antipsychotic drugs in psychiatric inpatients. Nippon Hoigaku Zasshi 1997; 51: 417-422
  PubMedGoogle Scholar
• 657 Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther 2007; 29: 2654-2666
  CrossrefPubMedGoogle Scholar
• 658 Topiwala A, Fazel S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev Neurother 2011; 11: 53-63
  CrossrefPubMedGoogle Scholar
• 659 Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 2006; 62: 645-651
  CrossrefPubMedGoogle Scholar
• 660 Touw DJ, Neef C, Thomson AH et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005; 27: 10-17
  CrossrefPubMedGoogle Scholar
• 661 Trivedi MH, Rush AJ, Gaynes BN et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacol 2007; 32: 2479-2489
  CrossrefPubMedGoogle Scholar
• 662 Tsai MH, Lin KM, Hsiao MC et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11: 537-546
  CrossrefPubMedGoogle Scholar
• 663 Tuerck D, Wang Y, Maboudian M et al. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 2007; 45: 662-668
  PubMedGoogle Scholar
• 664 Turbott J, Norman TR, Burrows GD et al. Pharmacokinetics of nortriptyline in elderly volunteers. Commun Psychopharmacol 1980; 4: 225-231
  PubMedGoogle Scholar
• 665 Turpeinen M, Koivuviita N, Tolonen A et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 2007; 64: 165-173
  CrossrefPubMedGoogle Scholar
• 666 Uchida H, Mamo DC, Mulsant BH et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009; 70: 397-405
  CrossrefPubMedGoogle Scholar
• 667 Uhr M, Steckler T, Yassouridis A et al. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387
  CrossrefPubMedGoogle Scholar
• 668 Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-239
  CrossrefPubMedGoogle Scholar
• 669 Ujiie Y, Fukasawa T, Yasui-Furukori N et al. Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam. Ther Drug Monit 2006; 28: 299-302
  CrossrefPubMedGoogle Scholar
• 670 Ulrich S, Baumann B, Wolf R et al. Therapeutic drug monitoring of clozapine and relapse – a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41: 3-13
  CrossrefPubMedGoogle Scholar
• 671 Ulrich S, Hiemke C, Laux G et al. TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. Pharmacopsychiatry 2007; 40: 121-127
  Article in Thieme ConnectPubMedGoogle Scholar
• 672 Ulrich S, Läuter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 2002; 41: 853-876
  CrossrefPubMedGoogle Scholar
• 673 Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 2005; 38: 171-177
  Article in Thieme ConnectPubMedGoogle Scholar
• 674 Ulrich S, Wurthmann C, Brosz M et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34: 227-263
  CrossrefPubMedGoogle Scholar
• 675 Valdes Jr R, Payne DA, Linder MW. (eds.) Laboratory medicine practice guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington, DC: National Academy of Clinical Biochemistry; 2010
• 676 Van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13: 169-172
  CrossrefPubMedGoogle Scholar
• 677 Van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005; 27: 478-483
  CrossrefPubMedGoogle Scholar
• 678 Van der Zwaag C, McGee M, McEvoy JP et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-1584
  PubMedGoogle Scholar
• 679 Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of Escitalopram overdose. Ann Emerg Med 2009; 54: 4-408
  PubMedGoogle Scholar
• 680 Van Putten T, Marder SR, Wirshing WC et al. Neuroleptic plasma levels. Schizophr Bull 1991; 17: 197-216
  PubMedGoogle Scholar
• 681 Varsaldi F, Miglio G, Scordo MG et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62: 721-726
  CrossrefPubMedGoogle Scholar
• 682 Vasudev K, Das S, Goswami U et al. Pharmacokinetics of valproic acid in patients with bipolar disorder. J Psychopharmacol 2001; 15: 187-190
  CrossrefPubMedGoogle Scholar
• 683 Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl) 2000; 150: 15-23
  CrossrefPubMedGoogle Scholar
• 684 Veefkind AH, Haffmans PMJ, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-208
  CrossrefPubMedGoogle Scholar
• 685 Velligan DI, Lam YW, Glahn DC et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006; 32: 724-742
  PubMedGoogle Scholar
• 686 Venkatakrishnan K, Culm KE, Ehrenberg BL et al. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol 2005; 45: 529-537
  PubMedGoogle Scholar
• 687 Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 1999; 39: 567-577
  PubMedGoogle Scholar
• 688 Vernaleken I, Fellows C, Janouschek H et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 2008; 28: 608-617
  CrossrefPubMedGoogle Scholar
• 689 Vernaleken I, Janouschek H, Raptis M et al. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol 2010; 13: 951-960
  CrossrefPubMedGoogle Scholar
• 690 Vernaleken I, Siessmeier T, Buchholz HG et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7: 421-430
  Google Scholar
• 691 Ververs FF, Voorbij HA, Zwarts P et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 2009; 48: 677-683
  CrossrefPubMedGoogle Scholar
• 692 Viala A, Ba B, Durand A et al. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl) 1988; 94: 293-297
  PubMedGoogle Scholar
• 693 Vine W, Bowers LD. Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring. Crit Rev Clin Lab Sci 1987; 25: 275-311
  CrossrefPubMedGoogle Scholar
• 694 Viola MS, Bercellini MA, Saidon P et al. Pharmacokinetic variability of oxcarbazepine in epileptic patients. Medicina (B Aires) 2000; 60: 914-918
  PubMedGoogle Scholar
• 695 Vogel F, Gansmüller R, Leiblein T et al. The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. Eur Psychiatry 2009; 24: 143-148
  CrossrefPubMedGoogle Scholar
• 696 Voineskos AN, Wilson AA, Boovariwala A et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) 2007; 193: 539-545
  CrossrefPubMedGoogle Scholar
• 697 Von Moltke LL, Greenblatt DJ, Giancarlo GM et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-1109
  PubMedGoogle Scholar
• 698 Von Moltke LL, Greenblatt DJ, Granda BW et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999; 48: 89-97
  PubMedGoogle Scholar
• 699 Vormfelde SV, Bitsch A, Meineke I et al. Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?. Eur J Clin Pharmacol 1997; 52: 387-390
  CrossrefPubMedGoogle Scholar
• 700 Vuille F, Amey M, Baumann P. Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 1991; 24: 190-195
  Article in Thieme ConnectPubMedGoogle Scholar
• 701 Waade RB, Christensen H, Rudberg I et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009; 31: 233-238
  CrossrefPubMedGoogle Scholar
• 702 Waldschmitt C, Vogel F, Maurer C et al. Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. Ther Drug Monit 2007; 29: 767-772
  CrossrefPubMedGoogle Scholar
• 703 Waldschmitt C, Vogel F, Pfuhlmann B et al. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey Pharmacopsychiatry 2009; 42: 189-193
  PubMedGoogle Scholar
• 704 Wan J, Xia H, He N et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 1996; 42: 471-474
  CrossrefPubMedGoogle Scholar
• 705 Wang JH, Liu ZQ, Wang W et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70: 42-47
  CrossrefPubMedGoogle Scholar
• 706 Ward E, Musa MN, Bailey LG. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994; 34: 280-285
  PubMedGoogle Scholar
• 707 Weber J, McCormack PL, Asenapine CNS. Drugs 2009; 23: 781-792
  PubMed
• 708 Weiden PJ, Kozma C, Grogg A et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-891
  CrossrefPubMedGoogle Scholar
• 709 Weigmann H, Bierbrauer J, Härtter S et al. Automated determination of clozapine and major metabolites in serum and urine. Ther Drug Monit 1997; 19: 480-488
  CrossrefPubMedGoogle Scholar
• 710 Weigmann H, Härtter S, Hiemke C. Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. J Chromatogr B Biomed Sci Appl 1998; 710: 227-233
  CrossrefPubMedGoogle Scholar
• 711 Weigmann H, Härtter S, Maehrlein S et al. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 759: 63-71
  CrossrefPubMedGoogle Scholar
• 712 Weiss U, Marksteiner J, Kemmler G et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25: 570-574
  CrossrefPubMedGoogle Scholar
• 713 Wen B, Ma L, Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact 2008; 173: 59-67
  CrossrefPubMedGoogle Scholar
• 714 Wen B, Zhou M. Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. Chem Biol Interact 2009; 181: 220-226
  CrossrefPubMedGoogle Scholar
• 715 White NC, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008; 4: 238-250
  CrossrefPubMedGoogle Scholar
• 716 Wienkers LC, Allievi C, Hauer MJ et al. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27: 1334-1340
  PubMedGoogle Scholar
• 717 Wiesel FA, Alfredsson G, Ehrnebo M et al. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 1980; 17: 385-391
  CrossrefPubMedGoogle Scholar
• 718 Wille SM, Cooreman SG, Neels HM et al. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 2008; 45: 25-89
  CrossrefPubMedGoogle Scholar
• 719 Willmore LJ, Abelson MB, Ben-Menachem E et al. Vigabatrin: 2008 update. Epilepsia 2009; 50: 163-173
  CrossrefPubMedGoogle Scholar
• 720 Wilson JF. Survey of reference ranges and clinical measurements for psychoactive drugs in serum. Ther Drug Monit 2003; 25: 243-247
  CrossrefPubMedGoogle Scholar
• 721 Wilting I, Heerdink ER, Mersch PP et al. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. Bipolar Disord 2009; 11: 434-440
  CrossrefPubMedGoogle Scholar
• 722 Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: preliminary results. J Clin Psychopharmacol 1991; 11: 48-51
  PubMedGoogle Scholar
• 723 Winter HR, Earley WR, Hamer-Maansson JE et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, Norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008; 18: 81-98
  CrossrefPubMedGoogle Scholar
• 724 Wójcikowski J, Boksa J, Daniel WA. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver – a comparison with other phenothiazines. Biochem Pharmacol 2010; 80: 1252-1259
  CrossrefPubMedGoogle Scholar
• 725 Wójcikowski J, Daniel WA. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism – an in vitro study. Pharmacol Rep 2009; 61: 851-858
  PubMedGoogle Scholar
• 726 Wójcikowski J, Pichard-Garcia L, Maurel P et al. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 2003; 138: 1465-1474
  CrossrefPubMedGoogle Scholar
• 727 Wolff K, Hay AW, Rasitrick D et al. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993; 44: 189-194
  CrossrefPubMedGoogle Scholar
• 728 Wong SL, Granneman GR. Modeling of sertindole pharmacokinetic dispositions in healthy volunteers in short term dose-escalation studies. J Pharmaceut Sci 1998; 87: 1629-1631
  CrossrefPubMedGoogle Scholar
• 729 Wong SL, Menacherry S, Mulford D et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997; 52: 223-227
  CrossrefPubMedGoogle Scholar
• 730 Wright CE, Sisson TL, Ichhpurani AK et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997; 37: 520-525
  PubMedGoogle Scholar
• 731 Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211-1214
  PubMedGoogle Scholar
• 732 Xiang Q, Zhao X, Zhou Y et al. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010; 50: 659-666
  PubMedGoogle Scholar
• 733 Xu P, Li HD, Zhang BK et al. Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects. J Clin Pharm Ther 2008; 33: 429-437
  CrossrefPubMedGoogle Scholar
• 734 Yao C, Raoufinia A, Gold M et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519-528
  PubMedGoogle Scholar
• 735 Yasui-Furukori N, Kondo T, Ishida M et al. The characteristics of side-effects of bromperidol in schizophrenic patients. Psychiatry Clin Neurosci 2002; 56: 103-106
  CrossrefPubMedGoogle Scholar
• 736 Yasui-Furukori N, Saito M, Nakagami T et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 286-291
  CrossrefPubMedGoogle Scholar
• 737 Yasui-Furukori N, Saito M, Nakagami T et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 2010; 24: 987-994
  CrossrefPubMedGoogle Scholar
• 738 Yeung PK, Hubbard JW, Korschinski ED et al. Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 1993; 45: 563-569
  CrossrefPubMedGoogle Scholar
• 739 Yin OQ, Wing YK, Cheung Y et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006; 26: 367-372
  CrossrefPubMedGoogle Scholar
• 740 Yu DK, Dimmitt DC, Lanman RC et al. Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. J Pharm Sci 1986; 75: 582-585
  CrossrefPubMedGoogle Scholar
• 741 Zernig G, Hiemke C, Havemann-Reinecke U et al. Empfehlungen für die gutachterliche Bewertung von Medikamentenspiegeln in der Psychiatrie im gerichtsanhängigen Schadensfall. Psychopharmakotherapie 2009; 16: 57-64
  PubMedGoogle Scholar
• 742 Zernig G, Lechner T, Kramer-Reinstadler K et al. What the clinician still has to be reminded of. Ther Drug Monit 2004; 26: 582
  CrossrefPubMedGoogle Scholar
• 743 Zernig G, Ng K, Hiemke C et al. Therapeutic drug monitoring-based clozapine dosing recommendations. Ther Drug Monit 2007; 29: 130-131
  CrossrefPubMedGoogle Scholar
• 744 Zhao Q, Iyer GR, Verhaeghe T et al. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol 2002; 42: 428-436
  PubMedGoogle Scholar
• 745 Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48: 689-723
  CrossrefPubMedGoogle Scholar
• 746 Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 2009; 48: 761-804
  CrossrefPubMedGoogle Scholar
• 747 Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89-295
  CrossrefPubMedGoogle Scholar
• 748 Zimmerman NP, Hickie IB, McGorry PD. Guidelines for youth depression: time to incorporate new perspectives. Med J Aust 2010; 193: 557
  PubMedGoogle Scholar
• 749 Zullino DF, Delessert D, Eap CB et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17: 141-143
  CrossrefPubMedGoogle Scholar